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 As legalization of cannabis continues to spread across the United States, many 
question the public health implications. The term “cannabis” is often used to refer to 
anything that comes from the plant and can be used recreationally (to get high or alter 
one’s current state) or medically (to treat a medical condition). While previous research 
has primarily focused on the impact of recreational cannabis use, few studies have 
examined cognitive outcomes associated with medical cannabis (MC) use and the 
potential for development of problematic use in MC patients. Given important 
distinctions among recreational users and MC patients, it is likely that these distinct 
populations of cannabis consumers will experience differential cognitive effects and 
potential for problematic cannabis use. 
This dissertation is comprised of three studies. The first is a cross-sectional study 
that explores executive function and verbal learning and memory in recreational cannabis 
users relative to healthy controls who do not use cannabis, while also assessing whether 
cannabis use patterns (e.g., age of onset, urinary THC levels) influence findings. The 
second study is an observational, longitudinal study which examines executive function 
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and memory, as well as changes in mood, anxiety, sleep, and quality of life in MC 
patients over 12 months of MC treatment relative to pre-MC treatment. In the third study, 
symptoms and behaviors associated with problematic cannabis use are examined in 
cohorts from study 1 and study 2.  Specifically, scores on the Cannabis Use Disorder 
Identification Test – Revised (CUDIT-R) are assessed in MC patients over the course of 
treatment and also compared to a previously recruited cohort of recreational cannabis 
users; the validity of the CUDIT-R is also explored.  
Despite previous research, in the current study recreational users did not exhibit 
cognitive decrements relative to healthy controls. In MC patents, cognitive performance 
was stable over the course of 12 months of MC treatment relative to pre-MC treatment 
performance, and overall they reported improved ratings of mood, anxiety, sleep, and 
some aspects of quality of life. Although the CUDIT-R suggests MC patients’ average 
scores do not meet the threshold for possible cannabis use disorder, analyses revealed this 
measure is not valid and therefore not appropriate in MC patients. 
Although changes in cognition were not detected in recreational users or MC 
patients in the current studies, a number of methodological limitations (e.g., sample size 
and limited ability to adjust for confounding variables) must be considered as these 
factors likely affected study results. Future studies evaluating the impact of cannabis use 
will benefit from carefully considering the definition of cannabis itself, goal of use, 
product choice, and age of onset of use. Researchers and clinicians will also benefit from 
the development of screening tools specifically designed to assess cannabis use disorder 
in those who use cannabis for medical purposes.  
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For the purposes of this dissertation, recreational cannabis users and medical cannabis 
patients are defined as follows: 
 
Recreational Cannabis Users – those who use cannabis products for the primary goal of 
feeling high or altering one’s current state of being 
 
Medical Cannabis (MC) Patients – those who 1) have a certification or physician’s 
recommendation to use cannabis or cannabinoid-based products for the main goal of 
relieving symptoms related to one or more chronic medical conditions; or 2) plan to use 
non-intoxicating, federally legal hemp-based products for the main goal of relieving 






CHAPTER ONE  
Brief History of Cannabis  
 Cannabis has been used for thousands of years; references to the use of cannabis 
for medicinal purposes appear in ancient texts and have been substantiated by evidence 
uncovered at archeological sites (Russo, 2007). However, public opinions of cannabis 
have changed drastically throughout the course of history, often due to political 
influences rather than scientific evidence. In the United States, cannabis-based therapies 
were widely used starting in the 19th century. In 1850, cannabis was added to the United 
States Pharmacopoeia (Bridgeman & Abazia, 2017), meaning that physicians could 
legally prescribe cannabis-based medications to their patients. During this time, 
numerous cannabis-based medications were patented and used to treat a variety of 
ailments. 
Recreational use of cannabis, defined as using cannabis to feel high or alter one’s 
current state of being, became part of the popular US culture in the early 1900s. Soon 
after, the US government began to restrict access to cannabis and an anti-cannabis 
revolution, often termed “Reefer Madness” after a 1936 film dramatizing the perils of 
cannabis use (Gasnier, 1936), ensued. This movement ultimately influenced popular 
views and attitudes towards cannabis, and in 1937, the Marihuana Tax Act made the sale 
of cannabis illegal. By 1942, cannabis was removed from the US Pharmacopeia, and in 
1970 it was placed in Schedule I of the Drug Enforcement Agency’s (DEA) Controlled 
Substances Act (CSA). Schedule I is the most restrictive category, which places cannabis 
alongside drugs like heroin and ecstasy. By definition, Schedule I substances have no 
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accepted medical value, high abuse liability, and no accepted safety profile (U.S. 
Department of Justice, 2019). Recently, this classification has been hotly contested, 
especially in light of a comprehensive review conducted by the National Academies of 
Science, Engineering and Medicine (NASEM). In this review, the authors stated they 
found “conclusive or substantial evidence” that cannabis/cannabinoids are effective for 
the treatment of three conditions: chronic pain, chemotherapy-induced nausea and 
vomiting, and muscle spasticity as a function of multiple sclerosis (NASEM, 2017). 
Specifically, the NASEM report concluded that treating chronic pain with cannabis is 
supported by well-controlled clinical trials based on 28 studies of cannabinoids for 
chronic pain, 22 of which utilized plant-derived (i.e., not synthetic) cannabinoids. For 
chemotherapy-induced nausea and vomiting, the authors reported that the evidence 
suggests synthetic, oral delta-9-tetrahydrocannabinol (THC) medications, were superior 
to placebo or equivalent to available antiemetic pharmaceutical treatments. Finally, 
randomized controlled trials examining both plant-derived and synthetic formulations of 
cannabinoids reported modest effect sizes for reductions of muscle spasticity in multiple 
sclerosis.  
While these results seem compelling, many studies included in the report assessed 
products that are not representative of the products actually available to MC patients, 
calling into question whether these conclusions are generalizable to those enrolled in MC 
programs, who purchase products at dispensaries, online retailers, or other point-of-sale 
locations. In other words, MC patients generally do not use products such as synthetic 
THC or nabiximols. However, conducting clinical trials of any commercially available 
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products derived from the cannabis plant is extremely difficult in the US given its 
Schedule I classification. Currently, cannabinoid formulations that can be studied in 
clinical trials must be synthetically-derived formulations, sourced from cannabis grown 
by the National Institute on Drug Abuse (NIDA), or (as of 2018) hemp-based products 
that are not currently for sale to consumers. Further, in addition to numerous other state 
and federal requirements and restrictions, researchers must hold a DEA Schedule I 
license to access plant-derived cannabis products from NIDA, which can be difficult to 
obtain especially amidst conflicting state and federal guidelines.  
In addition, not all studies included in the NASEM report meet rigorous standards 
typically utilized for evaluating pharmaceuticals and may have suffered from a high risk 
of bias and/or reflect only small effect sizes. Nonetheless, many see this review as an 
important cornerstone which, despite its limitations, suggests significant potential for 
cannabinoid-based treatments. Continued research assessing the therapeutic effects of 
cannabinoids is warranted not only for pain, chemotherapy-induced nausea/vomiting, and 
muscle spasticity related to multiple sclerosis, but also for the many other conditions that 
NASEM reviewed but found a lack of rigorous scientific studies from which to draw any 
definitive conclusions. Given current legal obstacles, as well as the complexities of the 
cannabis plant, although research on cannabis has been conducted for decades, many 





What is Cannabis? 
 Cannabis is a term used to describe the plant Cannabis Sativa L and, very often, 
any compounds derived from it. Although the botanical classification of cannabis has 
been debated over the years, cannabis is generally considered to have two main species, 
sativa and indica, although two less common species, ruderalis and afghanica, are also 
differentiated by some (Piomelli & Russo, 2016). Some anecdotal evidence suggests 
distinct effects for sativa and indica cultivars, where sativa is generally viewed as energy-
inducing, and indica is thought to have more relaxing effects (Hazekamp & Fischedick, 
2012); however, no empirical studies have directly assessed these claims. Given 
crossbreeding between sativa and indica plants, many believe that virtually all cultivars 
are a hybrid of the two strains, and as such cannabis may be better conceptualized as a 
single polymorphic species (Piomelli & Russo, 2016). 
Cannabis is comprised of hundreds of chemicals, including over 100 
phytocannabinoids, described as plant-derived compounds that interact directly with the 
body’s endogenous cannabinoid receptors or exhibit similar structure to other 
cannabinoids (Gertsch, Pertwee, & Di Marzo, 2010). Delta-9-tetrahydrocannabinol 
(THC) is typically the most abundant phytocannabinoid found in cannabis plants and is 
responsible for the intoxicating effects of cannabis. Although a number of non-
intoxicating phytocannabinoids exist, cannabidiol (CBD) is perhaps the most well-known 
and is often touted for its therapeutic properties (see Cannabinoids for more information).  
It is also important to note that the term, “hemp” is used to classify cannabis 
varieties that contain less than 0.3% THC by weight (Hemp Farming Act, H.R.5485 
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C.F.R., 2018). Hemp has traditionally been grown for industrial use (e.g., hemp fiber) 
and is therefore cultivated to maximize size and yield, which has resulted in cannabis and 
hemp plants looking different from one another, despite belonging to the same plant 
species (Andre, Hausman, & Guerriero, 2016). More recently, hemp plants (as well as 
some cannabis plants) have also been cultivated to make products high in CBD. 
The Endocannabinoid System 
A number of cannabinoids interact with the body’s endocannabinoid (eCB) 
system, a system responsible for maintaining homeostasis and for neuroplasticity, 
specifically neurogenesis, cell differentiation, and refinement of neuronal connections 
(Befort, 2015; Egerton, Allison, Brett, & Pratt, 2006; Katona & Freund, 2012; 
Maccarrone et al., 2015). Increased eCB signaling is related to reduced stress response, 
emotional regulation, and increased endogenous reward signaling (Befort, 2015; Hill & 
McEwen, 2010). Some preclinical studies also suggest a relationship between cognitive 
performance and activation of receptors within the endocannabinoid system (ECS) 
(Egerton et al., 2006). 
The ECS is comprised of two main types of cannabinoid receptors, CB1 and CB2, 
although some acknowledge a third receptor type, G protein-coupled receptor 55 
(GPR55) (Ryberg et al., 2007). Although CB1 and CB2 receptors are both found 
throughout the body, the majority of CB1 receptors are localized to the central nervous 
system, whereas CB2 receptors are mostly found in peripheral organs. The ECS also 
contains endogenous cannabinoids, including anandamide (AEA) and 2-arachidonoyl 
glycerol (2-AG), as well as a number of endocannabinoid-like compounds such as 
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palmitoylethanolamide (PEA) and O-Arachidonoyl-ethanolamine (OAE), among others. 
In addition, this system contains degradative enzymes: fatty acid amide hydrolase 
(FAAH) which degrades AEA, and monoacylglycerol lipase (MAG-L) which 
metabolizes 2-AG. The ECS is also affected by exogenous cannabinoids, including both 
phytocannabinoids and synthetic cannabinoids, which either bind directly to cannabinoid 
receptors, or moderate the ECS system via downstream effects. 
Phytocannabinoids vs. Synthetic Cannabinoids 
 Phytocannabinoids are defined as any cannabinoids that are derived from the 
cannabis plant. However, synthetic analogues of cannabinoids can also be created in a 
laboratory. Throughout this dissertation, unless otherwise noted, the focus will be on 
phytocannabinoids and plant-derived cannabis products rather than synthetically-derived 
compounds, such as nabilone and dronabinol, which are FDA-approved synthetic 
versions of THC that fall under Schedule II of the CSA. 
Cannabinoids & Additional Cannabis Constituents 
Cannabinoids 
THC, the cannabinoid responsible for the intoxicating effects of cannabis, is a 
partial agonist at both CB1 and CB2 receptors (Bolognini et al., 2013; Di Marzo & 
Piscitelli, 2015). As the ECS affects growth, differentiation, and connectivity of neurons, 
exposure to exogenous cannabinoids, particularly CB1 agonists like THC, may disrupt 
neural development, especially during adolescence. In fact, THC is typically considered 
responsible for the negative effects associated with cannabis use, including elevated risk 
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for cannabis use disorder (CUD) as well as symptoms of CUD (Freeman & Winstock, 
2015a; van der Pol et al., 2014). Exposure to THC has also been linked to psychotic 
symptoms (Di Forti et al., 2015; Large & Nielssen, 2017), cognitive decrements (Kowal 
et al., 2015; Ramaekers et al., 2006), and structural brain changes (Rigucci et al., 2016). 
As the majority of research citing the impact of “cannabis” typically assesses recreational 
cannabis users, results generally reflect the effects associated with THC given that THC 
is the most abundant cannabinoid contained in recreational products. Importantly, levels 
of THC appear to be rising in recreational cannabis products. Analyses of government-
seized cannabis flower revealed that between 1995 and 2017, average THC levels 
increased exponentially, rising from 3.96% in 1995 to 17.10% in 2017, an increase of 
332% (Chandra et al., 2019; ElSohly et al., 2016).  
In contrast to THC, CBD has low affinity for both CB1 and CB2 receptors and 
appears to exert its effects through indirect mechanisms and additional receptor types 
(Izzo, Borrelli, Capasso, Di Marzo, & Mechoulam, 2009; Zuardi, 2008). In fact, studies 
have identified more than 65 molecular targets of CBD; the most studied include 5HT1A 
receptors, GPR55, transient receptor potential (TRP) channels, and cytochrome P450s 
(Elsaid & Le Foll, 2020). However, CBD may also exert antiepileptic effects through N-
methyl-D-aspartate receptor (NDMA) receptors, anxiolytic effects through allosteric 
modulation of GABAA receptors, and antipsychotic effects via dopamine D2 receptors 
(Elsaid & Le Foll, 2020). 
CBD has become well known for its efficacy in treating severe pediatric-onset 
seizure disorders (Devinsky et al., 2016). In fact, in 2018, the Food & Drug 
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Administration (FDA) approved Epidiolex, a highly purified CBD product, for the 
treatment of severe pediatric-onset seizure disorders. As a result of this approval, the 
DEA placed Epidiolex under Schedule V of the CSA, acknowledging the therapeutic 
benefit and low abuse liability of this specific cannabinoid-based formulation.  
This multifaceted cannabinoid, which has demonstrated promise in treating a 
number of other medical conditions (Whiting et al., 2015), may also have to the potential 
to mitigate some of the negative effects associated with THC. For example, although 
THC is often said to be anxiogenic, particularly at high doses (Turna, Patterson, & Van 
Ameringen, 2017), evidence suggests that CBD has clear anxiolytic effects (Bergamaschi 
et al., 2011; Crippa et al., 2011; Zuardi, Shirakawa, Finkelfarb, & Karniol, 1982). Fusar-
Poli et al. (2009) demonstrated that 10 mg of THC increased anxiety, whereas 600 mg of 
CBD decreased anxiety in healthy individuals viewing fearful faces. In addition, CBD 
may protect against cognitive decrements (Morgan et al., 2012), neural alterations (Yucel 
et al., 2016), and THC-related psychotic-like symptoms (Bhattacharyya et al., 2010; 
Morgan et al., 2012). Specifically, one study found that individuals with higher THC 
levels (measured in hair samples) exhibited poorer performance on tests of episodic and 
verbal memory, but those who had detectable amounts of CBD demonstrated better 
recognition memory (Morgan et al., 2012). Further, higher THC levels were correlated 
with increased symptoms of depression and anxiety, while the presence of CBD was 
associated with lower scores on scales assessing psychotic-like symptoms. Yucel and 
colleagues (2016) found that the presence of CBD, also measured in hair samples, 
protected against structural hippocampal alterations associated with THC exposure. 
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Despite the therapeutic properties of CBD and potential ability to mitigate risk and harms 
of THC, CBD levels have declined to nearly undetectable levels in recreational products, 
while THC levels have risen dramatically. In fact, it is now estimated that the average 
THC:CBD ratio has gone from 14:1 in 1995 to 104:1 in 2017 (Chandra et al., 2019). 
Although vastly understudied, particularly in humans, additional cannabinoids, 
including cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), 
tetrahydrocannabivarin (THCV), and many others also appear to have therapeutic 
potential, such as anti-inflammatory and neurogenic effects (Borrelli et al., 2013; Izzo et 
al., 2009; Shinjyo & Di Marzo, 2013; Valdeolivas et al., 2015), as well as a role in 
preventing oxidative stress and inhibiting growth of certain cancers (De Petrocellis et al., 
2011; Pellati et al., 2018). For example, CBC has been shown to increase the viability of 
adult neural stem progenitor cells (Shinjyo & Di Marzo, 2013), and THCV appears to be 
neuroprotective, as study findings suggest it may also have the ability to inhibit some of 
the negative physiologic and cognitive effects of THC (Englund et al. 2016). More 
research is needed to elucidate the effects of these compounds, which are often termed 
“minor” cannabinoids, but studies are likely to become more prevalent as anecdotal 
evidence and preclinical studies reveal potential therapeutic applications.  
Terpenoids, Flavonoids, and the Entourage Effect 
Cannabis also contains other types of chemicals, including terpenoids and 
flavonoids. Terpenoids share a common precursor with phytocannabinoids and are the 
essential oils responsible for the various “flavors” and fragrances of different cannabis 
cultivars (i.e., strains of cannabis). Flavonoids are phenolic compounds, which typically 
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function as antioxidants and protect against oxidative stress in plants, including cannabis 
(Baron, 2018). Each of these constituents may also have biobehavioral effects alone 
and/or in combination with various cannabinoids.  
In addition to the unique effects of each individual cannabinoid, when terpenoids, 
cannabinoids, and other naturally occurring compounds (e.g., flavonoids) are all present 
together, many posit an “entourage effect,” which describes the synergistic actions that 
occur between these compounds and may result in stronger biobehavioral effects (Russo, 
2011). The entourage effect may help explain why products from whole-plant extractions 
known as “full spectrum” preparations, appear to be more efficacious than single-
compound extractions, sometimes referred to as “isolates” (Gallily, Yekhtin, & Hanuš, 
2015). In fact, a recent meta-analysis found that when patients used “CBD-rich” (i.e., 
full-spectrum) products, lower doses were required to achieve a therapeutic effect, and 
fewer adverse events were reported compared to “purified” (i.e., single compound) 
products (Pamplona, da Silva, & Coan, 2018). Although this meta-analysis is limited by 
the fact that studies reporting efficacy of CBD-rich products were all retrospective study 
designs, whereas studies of purified CBD product utilized prospective study designs, this 
meta-analysis provides preliminary empirical data to support anecdotal evidence of 
potential entourage effects. Research directly comparing full- or broad-spectrum products 




Cannabis Use Patterns in the United States 
 The most recent data from the National Survey on Drug Use and Health 
(NSDUH) suggest increasing rates of cannabis use; currently 43.8 million Americans 
aged 12 and older reported using cannabis within the past year, making it the second most 
widely used substance in the United States behind alcohol (Substance Abuse and Mental 
Health Services Administration, 2019). Rates of use also appear to be rising among 
certain age groups. According to the 2019 Monitoring the Future (MTF) survey, which 
tracks substance use patterns among the nation’s youth, daily cannabis use increased 
significantly among 8th graders and 10th graders relative to 2018 (National Institute on 
Drug Abuse, 2019). In addition, trends showed that vaping cannabis increased 
significantly in the past year among all age groups assessed (8th, 10th, and 12th graders). 
Some of the most common reasons 12th graders reported vaping include experimentation, 
an enjoyable flavor, enjoying time with friends, and to relax and relieve tension. The 
number of high school seniors reporting that they vape because they are “hooked” also 
doubled in the past year, which warrants further investigation.   
Statistics also suggest rising rates of cannabis use among other age groups in recent 
years, including young adults aged 18-25 (Substance Abuse and Mental Health Services 
Administration, 2019), and especially older adults aged 50 and over. In fact, older adults 
represent the largest growing population of cannabis consumers (Lloyd & Striley, 2018). 
From 2006/2007 to 2012/2013, the proportion of adults aged 55 and older who reported 
cannabis use in the past year increased by 71.4% from 2.8% to 4.8% (Han et al., 2017), 
and among those 65 and older, rates increased 250% from 0.4% to 1.4%. Further, more 
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recent data (Han & Palamar, 2020) also indicate that past year rates in those 65 and older 
rose significantly between 2015-2018 from 2.4% to 4.2%, representing another 75% 
increase in cannabis use among those in this age group. These fast-growing rates of use 
may be, at least in part, due to increased popularity of medical cannabis (MC) among 
older adults, who have higher rates of chronic medical disorders, including pain, mood 
disturbance, and insomnia.  
In terms of MC use, although the NSDUH, MTF, and similar surveys do not 
differentiate between recreational and medical cannabis use when reporting use rates, an 
independent survey estimates that approximately 3.7 million MC patients are currently 
registered in the US (Hudock, 2019). The most common indications reported for MC use 
include chronic pain, anxiety, and insomnia (Walsh et al., 2013). Interestingly, Haug et 
al. (2017) found that while middle-aged adults were more likely to use MC for insomnia, 
older adults were more likely to use MC for chronic medical conditions, including 
cancer, glaucoma and HIV/AIDS.  
Recreational vs. Medical Cannabis Use 
Although recreational and MC products are derived from the same plant species, 
inherent differences often exist between those who use cannabis recreationally and those 
who use medically. In the following chapters, “recreational” users are defined as 
individuals who use cannabis for the main purpose of feeling high or altering one’s state 
of consciousness, and the recreational users enrolled in the studies described in Chapter 2 
and 4 do not have underlying medical or psychiatric conditions. In contrast, MC patients 
are defined as those who have been certified for MC use to treat one or more underlying 
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medical condition or who choose to use federally legal hemp-based products, which are 
considered to be non-intoxicating, in order to treat an underlying condition(s).  
Although products sold to recreational users and MC patients can be the same, 
recreational users primarily seek products with considerable amounts of THC, as they 
desire the “high” or mood altering, often euphoric or mellowing, effects of cannabis 
(Wachtel, ElSohly, Ross, Ambre, & de Wit, 2002; Zeiger et al., 2010). In contrast, MC 
patients typically initiate use with the primary goal of symptom alleviation (Nunberg, 
Kilmer, Pacula, & Burgdorf, 2011), and often times look to actively avoid feelings of 
intoxication. As such, MC patients frequently seek products with rich and varied 
cannabinoid profiles (e.g., high-CBD products) that are more likely to confer a wide 
variety of medical benefits, relative to the traditional high-THC recreational products. 
However, this should not suggest that THC has no medical benefit or that MC patients do 
not use products containing THC. A number of studies have shown that THC appears to 
serve as an effective analgesic (De Vita, Moskal, Maisto, & Ansell, 2018), antiemetic, 
and appetite stimulant (Abrams, 2016; Walsh, Nelson, & Mahmoud, 2003). 
Although recreational users and MC patients may use cannabis in similar ways 
with regard to route of administration, it is also possible that these groups of cannabis-
using populations may choose distinct modes of use. Both recreational users and medical 
patients utilize traditional methods of cannabis consumption, including smoking, vaping 
and using edibles. However, some recreational users in particular have begun to utilize 
products with extremely high levels of THC, termed “concentrates,” also referred to 
colloquially as “dabs,” “wax,” “shatter,” “budder,” and a variety of other names based on 
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the products’ consistency. Recreational users who choose to use concentrates may utilize 
a method of administration known as “dabbing” in which a small amount of product (i.e., 
a “dab”) is placed on the extremely hot metal surface of a “dab rig” to vaporize it; the 
user subsequently inhales an extremely high dose of THC all at once (Sagar, Lambros, 
Dahlgren, Smith, & Gruber, 2018). On the other hand, MC patients may be more likely to 
utilize other novel modes of use, such as sublingual solutions, topicals, transdermals, and 
even suppositories. 
It is also important to recognize that while recreational users typically initiate use 
during adolescence and emerging adulthood, the majority of MC patients do not initiate 
MC treatment until they are adults/older adults, although there are exceptions, as in the 
case of those using Epidiolex or CBD products to treat severe epilepsy. Many studies 
assessing recreational cannabis users have demonstrated that earlier onset of cannabis use 
is related to poorer cognitive performance, which is likely due to exogenous cannabinoid 
exposure during the critical neurodevelopmental processes that take place during 
adolescence (Casey, Galvan, & Hare, 2005; Giedd et al., 1999; Gogtay et al., 2006). 
Accordingly, recreational users and MC patients may experience different effects given 
potential differences in their age of onset of cannabis use. 
Many hold strong views regarding cannabis, and it is often considered either a 
problem or a panacea. However, it is critical to assess factors associated with both the 
possible harms as well as the potential benefits of recreational versus medical cannabis 
use. Further, it is imperative to assess those enrolled in MC programs and/or using 
commercially available cannabinoid-based products to determine the overarching effects 
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of “real world” MC treatment. These data will provide important foundational 
information, which can ultimately be used to guide the development of cannabinoid-
based medicines that are optimized to treat specific conditions and to minimize potential 
for adverse effects and abuse liability. In the following chapters, the cognitive impact of 
recreational and medical cannabis use will be explored, as will symptoms and behaviors 




Recreational Cannabis Use & Cognition 
Public opinion of cannabis has shifted drastically in recent years, and current 
reports suggest up to two-thirds of Americans believe cannabis use should be legalized 
(Daniller, 2019). Changing attitudes toward cannabis are also reflected in data from the 
National Survey on Drug Use and Health (Substance Abuse and Mental Health Services 
Administration, 2017) which, according to data collected between 2012-2014, indicated 
that only 26.1% of people aged 12 or older believe monthly cannabis use is associated 
with “great harm.” As additional states have voted for legalization of recreational 
cannabis use since the publication of that study, it is likely that perceived risk and harm 
associated with cannabis use will continue to drop. Although there may be great potential 
for cannabis and cannabinoids as therapeutic alternatives to conventional medications, it 
is imperative to keep in mind that certain populations may be vulnerable and experience 
negative effects of cannabis use.  
In particular, children and adolescents are likely more vulnerable to the cognitive 
effects of cannabis use than older individuals given that they are in the midst of critical 
neuromaturation during this period. Between ages 10-12, children experience increased 
cerebral blood flow, an indicator of rapid neurodevelopment changes (Epstein, 1999). In 
fact, during this time myelination rates, cortical thickness (in frontal, temporal and 
parietal cortices), and amygdalar and hippocampal volume peak (Giedd et al., 1999; 
Tanaka, Matsui, Uematsu, Noguchi, & Miyawaki, 2012; Uematsu et al., 2012). At the 
start of puberty and continuing until at least the mid-20s, a period of synaptic pruning 
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occurs in these regions, leading to decreased volumes, and ultimately more efficient 
neural networks (Gogtay et al., 2006; Houston, Herting, & Sowell, 2014). During this 
period, white matter volume and integrity also increase, which are associated with 
improvements in neural conductivity (Giedd et al., 1999; Jernigan & Gamst, 2005).  
As the brain undergoes these important processes to refine and strengthen neural 
networks, the endocannabinoid system (ECS) likely plays a critical role. The ECS, 
known for maintaining homeostasis, also helps refine structural connectivity between 
neurons and contributes to neural growth (Di Marzo & Piscitelli, 2015; Garcia-Arencibia, 
Molina-Holgado, & Molina-Holgado, 2018). As a CB1 agonist, THC has the potential to 
alter functioning of the ECS and potentially interfere with expected neurodevelopmental 
trajectories. Accordingly, adolescence, which is also often marked by increased risk-
taking behaviors including experimentation with substance use, represents a period of 
vulnerability to exogenous influences, including cannabis. 
For decades, researchers have examined the impact of cannabis use on cognitive 
function, with mounting evidence suggesting that cannabis users, particularly those who 
begin using regularly during adolescence, exhibit cognitive decrements relative to healthy 
controls (Mashhoon, Sagar, & Gruber, 2019) or their own pre-cannabis use levels of 
performance (Jacobus et al., 2015; Squeglia, Jacobus, Nguyen-Louie, & Tapert, 2014). 
The majority of studies have focused on the effects of cannabis on executive function and 




Studies assessing executive function, including response inhibition, planning, and 
decision-making, demonstrate that recreational cannabis use appears to affect both 
current and recent users (Becker, Collins, & Luciana, 2014; Dougherty et al., 2013; 
Fontes et al., 2011; Hanson, Thayer, & Tapert, 2014; Harding et al., 2012; Infante et al., 
2019; Jacobus, Bava, Cohen-Zion, Mahmood, & Tapert, 2009; Sagar et al., 2015; 
Winward, Hanson, Tapert, & Brown, 2014). Several investigations have also reported 
that executive function serves as a predictor of cannabis use (Dahlgren, Sagar, Racine, 
Dreman, & Gruber, 2016; Squeglia et al., 2014) and cannabis-related problems (Day, 
Metrik, Spillane, & Kahler, 2013). A number of studies have also examined working 
memory, often considered a core facet of executive function. Findings suggest poorer 
performance among recreational cannabis consumers on some paradigms but not others 
(Broyd, van Hell, Beale, Yucel, & Solowij, 2016). 
Several reviews assessing memory function indicate that recreational cannabis use 
appears to affect a number of individual aspects of memory (Broyd et al., 2016; Ganzer, 
Broning, Kraft, Sack, & Thomasius, 2016; Solowij & Battisti, 2008). Findings within the 
memory domain are most robust for measures of verbal learning, where decrements have 
been observed in terms of encoding, recall, and recognition (Laspada et al., 2019; Solowij 
& Battisti, 2008); however, not all studies have observed an association between verbal 
learning decrements and cannabis use (Infante et al., 2019). It is also of note that findings 
assessing other aspects of memory function, including associative and visuospatial 
memory, are less clear. For example, only a handful of studies note decrements on 
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measures of visual short-term memory (Hermann et al., 2007; Sneider, Gruber, 
Rogowska, Silveri, & Yurgelun-Todd, 2013).  
Although the majority of studies generally conclude that heavy, recreational 
cannabis use is related to adverse changes in executive function/working memory as well 
as verbal memory, some have argued that these decrements, which are often variable 
across studies, may be related to other factors and/or may not be clinically significant. In 
fact, a recent study, which examined twins discordant for cannabis use, reported that 
although cannabis use was related to poorer cognitive functioning, associations were 
either no longer observed after accounting for other substance use, or may be explained 
by lower cognitive functioning before initiation of cannabis use; overall, the authors 
concluded that the relationship between cannabis use and cognition is likely not causal 
(Ross et al., 2019).  
Scott et al., (2018) conducted a meta-analysis of 69 studies of recreational 
cannabis users and concluded that although poorer cognitive function was associated with 
frequent or heavy cannabis use, the effect size was small overall. Further, among the 15 
studies requiring more than 72 hours of cannabis abstinence, effect sizes were not only 
smaller than those studies with less rigorous abstinence criteria, but the effect sizes for 
these studies were not significantly greater than zero. Lovell, Akhurst, Padgett, Garry, 
and Matthews (2019) conducted a meta-analysis that suggested significant, albeit small, 
decrements in memory and executive functioning. The authors of this analysis concluded 
that recreational cannabis users who use regularly for prolonged periods of time might 
experience cognitive decrements, which ultimately result in poorer performance on 
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everyday tasks, including driving. Interestingly, these findings support a recent driving 
simulator study which suggest that in the absence of acute intoxication, cannabis users 
exhibit poorer driving performance than healthy controls, and that poorer performance 
appears to be localized to those who initiated regular use prior to age 16 (Dahlgren et al., 
2020). 
Taken together, it is imperative to continue to assess the cognitive impact of 
recreational cannabis use in light of recent trends, including increased potency of 
cannabis flower (Chandra et al., 2019), growing popularity of cannabis concentrates, and 
the advent of novel modes of use (e.g., dabbing), designed to deliver large doses of THC 
all at once (Sagar et al., 2018), as each of these factors has the potential to confer greater 
negative effects. The current study is designed to expand upon a previously published 
investigation (Gruber, Sagar, Dahlgren, Racine, & Lukas, 2012), which examined 
cognitive performance in chronic, heavy recreational cannabis users and found that 
poorer performance on tasks of executive function noted in cannabis users relative to 
healthy controls was primarily attributable to those with early onset of cannabis (regular 
use prior to age 16).   
Hypotheses 
Utilizing the previous sample (Gruber, Sagar, Dahlgren, Racine, et al., 2012) as 
well as newly recruited participants, it was hypothesized that cannabis users would 
display poorer performance on tasks of executive function and working memory relative 
to healthy controls and late onset cannabis users. In addition, given larger sample sizes, it 
was also hypothesized that decrements in verbal learning and memory, which were not 
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previously observed but have been noted widely throughout the literature, would be 
detected. Further, given the neurodevelopmental vulnerability of those who initiate use 
prior to age 16 as well as prior findings, it was also hypothesized that early onset 
cannabis users would perform significantly more poorly than healthy controls across 
cognitive measures, while findings would be less prominent in late onset users relative to 
healthy controls.  
Methods 
Participants 
Participants included individuals recruited serially for three separate, but similar 
studies all designed to assess cognitive and clinical outcomes associated with recreational 
cannabis use. These three studies were conducted at McLean Hospital and funded by 
National Institute on Drug Abuse (NIDA) grants awarded to Dr. Staci Gruber (Frontal 
Neural Mechanisms and Risk for Substance Abuse, R03 DA016695; Marijuana and 
Mood: Frontal Predictors of Behavior, R21 DA021241; and Marijuana: Neurobiologic 
Correlates of Age of Onset, R01 DA03264601). Seventy-nine (66 male, 13 female) well-
characterized, chronic, heavy, cannabis users (CAN) were included in this investigation, 
as well as 48 (28 male, 20 female) non-cannabis using healthy control (HC) participants. 
The CAN group was further divided into early (n=38) and late onset (n=40) groups based 
on age of onset of regular cannabis use. Although no uniformly accepted definition of 
early or late onset exists, a number of studies have used age 16 to differentiate early 
versus late cannabis use onset (Ehrenreich et al., 1999; Gruber, Dahlgren, Sagar, Gonenc, 
& Killgore, 2012; Gruber, Sagar, Dahlgren, Racine, et al., 2012; Gruber, Silveri, 
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Dahlgren, & Yurgelun-Todd, 2011; Kempel, Lampe, Parnefjord, Hennig, & Kunert, 
2003). In order to ensure results are comparable to previous analyses, early onset was 
defined as regular cannabis use prior to age 16, while late onset was defined as regular 
use at age 16 or later.  
Study participants were recruited from both urban and suburban locations within 
the Greater Boston area, including local colleges and universities, gyms, supermarkets, 
community centers, and other public locations. The Structured Clinical Interview for 
Diagnostic and Statistical Manual of Mental Disorders [DSM-IV], Patient Edition (SCID-
P) was administered to ensure all participants were free of Axis I pathology, including 
current or previous drug or alcohol abuse or dependence (but excluding cannabis 
abuse/dependence for the CAN group). In addition, participants were excluded if they 
reported binge drinking (5 or more drinks for males, and 4 or more drinks for females, 
within 2 hours), routinely had more than 15 drinks per week, or if they reported more 
than 15 lifetime uses of any category of illicit drugs. Upon arrival at the laboratory, 
participants also had to provide a urine sample and were excluded if they tested positive 
for other drugs (amphetamines, cocaine, THC, methamphetamine, opioids, 
phencyclidine, benzodiazepines, methadone, MDMA) according to an in-house drug 
assay (with the exception of THC for the CAN group).  Current or previous use of 
psychotropic medications, history of neurological disorders or head injury with loss of 
conscious for more than five minutes were also considered exclusionary.  
In order to qualify for study entry, cannabis users had to report a minimum of 
1500 lifetime cannabis uses, use cannabis at least four of the last seven days, and test 
 
23 
positive for urinary cannabinoids (assessed using the in-house drug assay). Cannabis 
users were required to abstain from using cannabis for at least 12 hours prior to their 
study visit to ensure that they were not acutely intoxicated at the time of assessment. Any 
participants who reported use within the required abstinence period as assessed using a 
modified, detailed timeline followback (TLFB) procedure (Robinson, Sobell, Sobell, & 
Leo, 2014a; Sobell, Sobell, Leo, & Cancilla, 1988), or who appeared intoxicated based 
on staff’s clinical judgment were rescheduled for a later date. All participants were 
required to be native English speakers, as necessitated by the cognitive test battery. 
Study Design 
Prior to participation, all study procedures were explained, and participants were 
required to read and sign an informed consent form, which described the procedures of 
the study and explained that participation was voluntary. This study was approved by the 
Partners Healthcare Institutional Review Board. 
This study utilized a cross-sectional design to compare healthy, non-cannabis-
using controls (HCs) to chronic heavy, recreational cannabis (CAN) users, and to 
compare HCs to early onset CAN users (regular cannabis use prior to age 16), and late 
onset CAN users (regular cannabis use at age 16 or later). Participants were asked to 
report the first time they tried cannabis and answer questions about their use patterns, 
including age of onset of regular use (once per month or more); general use patterns were 
then documented from that point to the present. Current use was assessed using a 
customized TLFB procedure, which supplements the traditional, validated TLFB 
methods (Sobell et al., 1998) with additional queries designed to facilitate recollection of 
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their initial use (e.g., Who where you with? Where were you when this happened?) and 
subsequent patterns of use. Participants are asked to report frequency of use, mode of use 
(smoking, vaping, edibles, concentrates, etc.), and amount of cannabis used (in grams). It 
is well known that quantifying the actual amount of cannabis used is often difficult to 
ascertain using self-report methods, but the optimized TLFB procedure required 
participants to report their use in a variety of ways and in great detail to help corroborate 
initial self-reports of use (e.g., How much cannabis do you typically use each time you 
use it? How much cannabis do you buy? How long does the amount purchased last? Do 
you share cannabis with others, and if so how many others?). In addition, visual aids 
were used which depict how much given weights (grams) of cannabis look like in real 
life across various product types. Further, a portion of the urine sample acquired for the 
in-house drug screen was also sent to an outside laboratory for quantification of urinary 
concentration of THC metabolites via gas chromatography–mass spectrometry (GC–MS). 
THC was normalized to creatinine (Cr) level in order to minimize the effects of 
metabolism. In addition, a subset of participants (those recruited for R01 DA03264601) 
completed a modified version of the Marijuana Withdrawal Checklist (MWC) (Budney, 
Novy, & Hughes, 1999), a 16-item self-report scale in which respondents rate current 
symptoms associated with cannabis withdrawal (e.g., irritability, craving, etc.) using a 0-
3 point scale (none, mild, moderate, or severe); total scores on this version of the MWC 
range from 0-48.   
Participants also completed scales to assess nicotine use, alcohol use, and 
impulsivity. The Fagerstrom Test for Nicotine Dependence (FTND) is a 6-item scale 
 
25 
scored from 0 to 10, where higher scores indicate more severe nicotine addiction. The 
Addiction Severity Index (ASI) was used to provide the number of days in the past 30 
that the participant drank alcohol. The Barratt-Impulsiveness Scale (BIS-11) is self-report 
measure, which examines several aspects of impulsivity, including attention (e.g., “I 
don’t pay attention”), motor impulsivity (e.g., “I act on impulse”), and non-planning (e.g., 
“I say things without thinking”). A total impulsiveness score was calculated to reflect 
overall levels of impulsivity; total scores can range from 30-120 where higher scores are 
indicative of higher levels of impulsivity. 
All subjects completed a battery of neuropsychological tests over one to two 
visits. An estimated IQ was first ascertained using the Wechsler Abbreviated Scale of 
Intelligence (WASI) (Wechsler, 1999). For the WASI, total raw scores on each subtest 
are converted to T scores, and T scores are summed in order to calculate a full-scale IQ 
estimate; these IQ scores are based on a nationally representative normative sample. A 
number of additional tests were utilized to assess various aspects of executive function as 
well as verbal learning and memory given that previous research suggests that these 
domains are the most sensitive to cannabis use. In order to minimize multiple 
comparisons, the most relevant variables were chosen from a larger battery of tests, and 
include Stroop Interference Time, Trails B Time, Wisconsin Card Sorting Test (WCST) 
Categories, WCST Perseverative Errors, Letter Number Sequencing (LNS), Phonemic 
Fluency, California Verbal Learning Test (CVLT) Trials 1-5 Correct, CVLT Short Delay, 
and CVLT Long Delay. Each of these task variables are described below. 
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The Stroop Color Word Test (MacLeod, 1991) is a widely used measure of 
executive function. The task is comprised of three conditions: color naming (participants 
name blocks of colors), word reading (participants read words printed in black ink), and 
interference, the latter of which examines the ability to establish competing response 
tendencies, inhibit inappropriate responses, and resist interference. During this condition, 
participants are presented with color words printed in an incongruous ink color (e.g., 
“RED” printed in green ink); they must inhibit the natural tendency to read the words and 
instead must name the color of the ink. Performance was assessed by interference 
completion times; lower numbers (i.e., faster times) are indicative of better performance. 
The Trail Making Test (Lezak, Howieson, Bigler, & Tranel, 2012) is divided into 
two parts. Trails A measures psychomotor speed and attention (participants connect a 
series of numbered circles), whereas Trails B is considered a measure of executive 
function, as it utilizes an alternative set-shifting demand to measure cognitive flexibility 
(participants alternate between connecting numbers and letters). Performance on this task 
was measured by the time to complete Trails B. Maximum time allowed is 180 seconds, 
and faster times (i.e., lower numbers) indicate better performance. 
The WCST, often considered the ‘gold standard’ measure of executive function, 
assesses the ability to shift and maintain set and ability to adjust one’s behavior by 
utilizing feedback (Berg, 1948). Participants are given a deck of 64 cards and must sort 
them according to specific criteria, which unbeknownst to the participant, changes 
throughout the task. Participants must adjust to the new sorting principle based on 
examiner feedback (whether each sort is correct or incorrect). Primary variables for 
 
27 
analyses included categories completed (higher numbers are better and can range from 0-
6) and number of perseverative errors (lower numbers are better). 
The LNS task (Wechsler, 1987) was also utilized to assess executive function and 
working memory abilities. During this task, the examiner reads increasingly longer 
strings of numbers and letters, and participants are asked to re-sequence the string of 
characters by repeating the numbers in order, followed by the letters in alphabetical 
order. There are 21 potential sequences, and the total number of correct sequences serves 
as the primary outcome variable.  
The Phonemic Fluency task is considered a measure of executive function. During 
this task, participants must generate words beginning with three specific letters within a 
60 second time frame for each letter (Lezak et al., 2012). The number of unique words 
generated across all three letters given is calculated, and higher scores reflect better 
performance. 
The CVLT is a measure of verbal learning and memory (Delis, Karmer, E., & 
Ober, 1987). During this task, participants are presented with a list of 16 words over the 
course of five trials and must remember as many words as they can. Overall verbal 
learning is measured by the number of correct responses over all five trials (Trials 1-5 
Correct). After the presentation of a distractor list, verbal memory is assessed 
immediately (Short Delay) and again after a 20-minute delay (Long Delay). For total 
correct responses over Trials 1-5, the maximum score is 80, and for both delay variables, 




Descriptive statistics (e.g. mean and standard deviation) were calculated for 
demographic (age, education, IQ, days of alcohol intoxication, FTND and BIS-11 scores) 
and cannabis use variables. Analyses were conducted to assess the HCs vs CAN users, 
while additional comparisons (HC vs early onset CAN and HC vs late onset CAN) were 
used to examine the impact of age of onset of cannabis use relative to HCs. Specifically, 
in order to assess any potential demographic differences between groups, chi-squared 
analyses were used to compare sex and race (white vs non-white) frequencies between 
the HC and CAN groups, and for continuous variables (age, IQ, education, frequency of 
cannabis use, magnitude of cannabis use, and duration of cannabis use), one-way 
analyses of variance (ANOVAs) were conducted.  
Cognitive performance data were screened for outliers, and any individual that 
had an estimated IQ of 85 or lower was removed from all analyses; 4 participants (1 HC, 
2 early onset CAN users, 1 late onset CAN user) were removed, resulting in final samples 
sizes of 47 HCs and 76 CAN users, of which 36 were early onset and 40 were late onset 
users. For cognitive data, although raw scores were utilized, one-way analyses of 
covariance (ANCOVAs) were conducted, controlling for age, sex, and education when 
comparing HCs vs all recreational CAN users, HCs vs Early Onset CAN users, and HCs 
vs Late Onset CAN users. Results from each of these analyses are reported with effect 
sizes (partial eta squared) and 95% confidence intervals which are based on estimated 
marginal means. All analyses of cognitive performance were Bonferroni-corrected for 
multiple comparisons: α≤.05/6=.008 for tasks in the executive function domain, and 
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α<.05/3=.017 for tasks in the verbal learning and memory domain. The few cases where 
Levene’s test of equality of error variance was violated are noted in within the results 
tables; however, for all comparisons where the assumption of homogeneity was violated, 
ANCOVA results were not significant. Therefore, it would be unlikely that non-
parametric statistics with reduced statistical power would produce significant findings. 
As significant differences were not noted between-groups, exploratory analyses 
were also conducted to determine whether, within the CAN users, cognitive performance 
may be related urinary THC levels; these analyses were conducted in light of the fact that 
potency of cannabis products is rising and may be an important factor to consider in 
subgroups of CAN users who utilize products with higher levels of THC. Partial 
correlations controlling for age, sex, and education (2-tailed) were utilized for these 
preliminary analyses. 
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Demographics & Cannabis Use 
 Forty-seven HCs and 76 recreational CAN users were included in the current 
analyses, after excluding 1 HC and 3 CAN users as IQ outliers. Among CAN users, 36 
were characterized as early onset (onset of regular use prior to age 16) and 40 were 
characterized as late onset (onset of regular use at age 16 or later). Demographics are 
presented for HC vs CAN users in Table 2.2; HC vs early onset and HC vs late onset 
CAN users are presented in Table 2.3.  
Overall, HCs and CAN users were well matched for age, IQ, race, and levels of 
nicotine dependence (FTND scores). Participants were generally young adults in their 
early twenties with well above average IQ scores. Approximately three-quarters of 
individuals enrolled in the HC and CAN groups were white, and participants reported 
zero to minimal levels of nicotine dependence on the FTND. However, a number of 
significant differences emerged between the two groups for other demographic variables. 
Sex distribution, education, days of alcohol use (in the past 30 days), and BIS-11 
impulsivity scores were significantly different between groups; the CAN group was 
comprised of a smaller proportion of females, had about one year less of education, drank 
alcohol more frequently, and had higher self-reported impulsivity relative to HCs. 
When comparing HCs to early and late onset CAN users, the groups had similar 
age, IQ, and race frequencies. However, the proportion of female participants was 
significantly higher in the HC group relative to both the early and late onset groups. In 
addition, HCs had completed more years of education than early onset CAN users, but no 
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differences were observed for education between HCs and late onset users. Comparisons 
of impulsivity, alcohol and nicotine use also revealed significant between-group 
differences. BIS-11 impulsivity scores were significantly elevated in the early and late 
onset CAN groups relative to HCs. Both early and late onset CAN users reported higher 
alcohol use than HCs. In addition, early onset CAN users reported significantly higher 
levels of nicotine dependence than HCs. However, this difference is attributed to the fact 
that HCs all reported an FTND of 0, and although early onset users had higher scores, on 
average ratings were not indicative of nicotine dependence and reflect only light nicotine 
use in a handful of early onset CAN users. 
 In terms of cannabis use (see Table. 2.4), early and late onset users were well-
matched on the majority of cannabis use variables with the exception of age of onset of 
use, which was expected given that this variable was used to stratify the two groups, and 
grams of cannabis used per week; the early onset group reported using almost twice as 
much cannabis as the last onset group. Both early and late onset users reported similar 
duration of cannabis use and episodes of cannabis use per week. Urinary THC levels also 
did not differ significantly between groups. On the MWC, both groups had similar low 













Sexa 27 (57.4%) Male 20 (42.6%) Female 
63 (82.9%) Male 
13 (17.1%) Female 9.58 <.01 
Racea 35 (74.5%) White 12 (25.5%) Non-White* 
59 (78.7%) White 
16 (21.3%) Non-White* 0.29 .59 
 Mean (SD)  
Median 




F p (η2) 
Ageb 24.19  (6.70) 
22 
[18-47] 23.33 (6.25) 
21.5 
17-46 0.52 .47 (<.01) 
Educationb 15.26 (2.22) 16 [12-21] 14.07 (1.93) 
14 
[10-20] 9.72 <.01 (.07) 
WASI IQc 122.41 (11.17) 124.5 [88-142] 119.38 (11.20) 
120.5 
[89-144] 2.10 .15 (.02) 
FTNDd† 0.00 (0.00) 0 [0-0] 0.19 (0.69) 
0 
[0-4] 2.47 .12 (.03) 
Days of alcohol 
use in past 30e 4.59 (4.93) 
3 
[0-20] 7.06 (5.35) 
5.5 
[0-20] 6.43 .01 (.05) 
BIS-11 Total 
Impulsiveness f 55.82 (11.09) 
52.5 
[38-84] 64.76 (10.07) 
64.5 
[38-82] 19.96 <.01 (.15) 
Significant values (p≤.05) are bolded 
 
WASI= Wechsler Abbreviated Scale of Intelligence, FTND = Fagerstrom Test for Nicotine Dependence, BIS-11=Barratt Impulsiveness Scale  
 
*Healthy Controls: Non-white=2 Black, 9 Asian, 1 Other; Recreational Cannabis Users: Non-white= 9 Black, 4 Asian, 2 Multiracial 
 
 
†Levene’s test of equality of error variances was violated; however, non-parametric Kruskal-Wallis tests also indicated no significant 
difference between groups (X2=2.94, p=.09) 
 
 
aDegrees of freedom (df)=1; bdf=1,121; cdf=1,120; ddf=1,87; edf=1,115; fdf=1,114 














HC vs Early 
Chi-Square 
HC vs Late 
Chi-Square 
Demographics n=47 n=36 n=40 X2 p X2 p 
Sexa 27 (57.4%) Male 20 (42.6%) Female 
31 (86.1%) Male 
5 (13.9% Female) 
32 (80.0%) Male 
8 (20.0%) Female 7.96 <.01 5.03 .03 
Racea 35 (74.5%) White 12 (25.5%) Non-White* 
30 (83.3%) White 
6 (16.7%) Non-White* 
29 (74.4%) White 
10 (25.6%) Non-White* 0.94 .33 0.00 .99 











HC vs Early 
ANOVA 
HC vs Late 
ANOVA 
F p (η2) F p (η2) 




























































Days of alcohol 



































Significant values (p≤.05) are bolded 
 
 
WASI= Wechsler Abbreviated Scale of Intelligence, FTND = Fagerstrom Test for Nicotine Dependence, BIS-11=Barratt Impulsiveness Scale 
 
*Healthy Controls: Non-white=2 Black, 9 Asian, 1 Other; Early Onset: Non-white= 3 Black, 1 Asian, 1 Multiracial; Late Onset: Non-white= 6 Black, 
3 Asian, 1 Multiracial 
 
aDegrees of freedom (df)=1; bdf=2,120; cdf=2,119; ddf=2,86; edf=2,114; fdf=2,113 
 
†Levene’s test of equality of error variances was violated; however, non-parametric Kruskal-Wallis tests did not impact results 














Early vs Late 
ANOVA 
Cannabis Use Mean  (SD) 
Median 
[Range] 







[Range] F p (η
2) 
Age of onseta† 16.00 (2.20) 
16 
[11-23] 





















[2.05-63.00] 3.33 .07 (.05) 
Grams/weekb† 8.17  (11.40) 
4.50 
[0.27-74.39] 





































[27.67-2595.00] 1.49 .21 (.03) 
MWC d 6.62  (3.64) 
6 
[1-15] 







[1-12] 0.96 .33 (.03) 
Significant values (p≤.05) are bolded 
 
 
THC/Cr=delta-9-tetrahydrocannabinol/Creatinine, MWC=Marijuana Withdrawal Checklist 
 
 
a n=76 All users, n=36 Early onset, n=40 Late onset  
b n=74 All users, n=36 Early onset, n=38 Late onset 
c  n=51 All users, n=22 Early onset, n=30 Late onset 
d n=37 All users, n=15 Early onset, n=22 Late onset 
 
†Levene’s test of equality of error variances was violated; however, non-parametric Kruskal-Wallis tests did affect significance of result 





 See Table 2.5 (HC vs CAN) and Table 2.6 (HC vs Early Onset and HC vs Late 
Onset) for cognitive performance data. On measures of executive function (Stroop 
Interference, Trails B Time, WCST Categories and Perseverative Errors, LNS, and 
Phonemic Fluency) no significant between-group differences were noted between healthy 
controls and recreational cannabis users. Similarly, when comparing HCs to early onset 
and late onset users, no significant differences were observed. 
  Similarly, on the CVLT, a measure of verbal learning and memory, ANCOVAs 
comparing healthy controls to recreational users did not detect any significant between-
group differences that surpassed the Bonferroni-corrected significance threshold. In 
addition, analyses of HCs vs early onset and HCs vs late onset CAN users did not reveal 











  Task Variable Mean (SD) Mean (SD) 
F 
[95% CI] p (η
2) 
Executive Function     
   Stroop Interference Timea 88.13 (14.86) 90.32 (21.68) 0.01  [-6.99, 7.83] .91 (<.01) 
   Trails B Time (sec)b 44.11 (13.56) 51.76 (17.34) 2.49 [-11.13, 1.26] .12 (.02) 
   WCST Categoriesc 4.24 (1.26) 3.87 (1.21) 0.26 [-0.36, 0.62) .61 (<.01) 
   WCST Perseverative Errorsc† 4.07 (3.82) 6.64 (6.35) 2.08 [-4.04, 0.64] .15 (.02) 
   LNSd 12.81 (2.51) 12.73 (2.98) 0.19 [-1.44, 2.24] .66 (<.01) 
   Phonemic Fluencye 48.29 (9.04) 48.13 (11.61) 0.37 [-6.18, 3.28] .55 (<.01) 
Verbal Learning & Memory 
   CVLT Trials 1-5 Correctf 58.44 (7.84) 53.51 (9.20) 4.36 [0.18, 6.96] .04 (.04) 
   CVLT Short Delayf 12.73 (2.66) 11.50 (2.70) 2.95 [-0.14, 2.01] .09 (.03) 
   CVLT Long Delayh 13.11 (2.41) 11.93 (2.78) 3.09 [-0.12, 2.00] .08 (.03) 
Analyses of covariance (ANCOVA) were not significant after Bonferroni corrections: p≤.05/6=.008 for 
Executive Function tasks, and p<.05/3=.017 for Verbal Learning and Memory tasks. Results that were 
significant before Bonferroni corrections are italicized. 
 
†Levene’s test of equality of error variances was violated; however, non-parametric Kruskal-Wallis tests 
yielded the same results as the ANOVAs 
 
aDegrees of freedom (df)=1,113; bdf=1,117; cdf=1,106; ddf=1,48; fdf=1,89; gdf=1,110; hdf=1,109 
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ANCOVA 
HC vs Late 
ANCOVA 
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Executive Function    






















































Verbal Learning & Memory    



























Analyses of covariance (ANCOVA) were not significant after Bonferroni corrections: p≤.05/6=.008 for Executive Function tasks, and p<.05/3=.017 
for Verbal Learning and Memory tasks. Results that were significant before Bonferroni corrections are italicized. 
 
aHC vs Early: df=1,77; HC vs Late: df=1,79    bHC vs Early: df=1,77; HC vs Late: df=1,82 
cHC vs Early: df=1,70; HC vs Late: df=1,73    dHC vs Early: df=1,26; HC vs Late: df=1,33 
eHC vs Early: df=1,57; HC vs Late: df=1,67    fHC vs Early: df=1,74; HC vs Late: df=1,77 
gHC vs Early: df=1,73; HC vs Late: df=1,77 
†Levene’s test of equality of error variances was violated; non-parametric Kruskal-Wallis tests yielded the same results as the ANOVAs  
Table 2.6 HC vs Early Onset CAN vs Late Onset CAN: Cognitive Performance  
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Correlations: Cannabis Use vs Cognitive Performance 
Although significant findings were not observed between groups after correcting 
for multiple comparisons, exploratory partial correlations (controlling for age, education, 
and sex) were utilized in order assess whether overall exposure to THC may influence 
cognitive performance. Results revealed that higher urinary THC levels were associated 
with slower completion times on Trails B (r(49)=.37, p=.01). Significant findings were 
not observed between any other cognitive performance variable and urinary THC levels.  
Discussion 
 It was hypothesized that heavy recreational cannabis users would exhibit 
decrements on tasks of executive function as well as verbal learning and memory; 
however, significant between-group differences were not observed. It was also 
hypothesized that once cannabis users were divided into those with early onset (before 
16) versus late onset (age 16 or alter) of regular cannabis use, early onset users would 
demonstrate decrements relative to healthy controls. However, significant differences 
were also not observed for these comparisons. These findings are in contrast to a large 
number of studies that have reported poorer executive function and memory decrements 
in recreational cannabis users, particularly those with early onset of use (Crane, Schuster, 
Fusar-Poli, & Gonzalez, 2013; Crean, Crane, & Mason, 2011; Lisdahl, Wright, Kirchner-
Medina, Maple, & Shollenbarger, 2014; Sagar & Gruber, 2018b; Solowij & Battisti, 
2008). Although it is possible that results suggest recreational cannabis use itself does not 
cause decrements in cognitive function, which has been reported previously (e.g., Ross et 
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al., 2019), it is likely that null findings in the current study may be related to a number of 
important factors. 
 First, it is possible that results were influenced by ceiling effects, as participants 
in both groups generally performed quite well across many study measures. In fact, 
participants in the current study had very high estimated IQ (average across all 
participants: 121.06), which has been observed in similar previous studies conducted at 
McLean Hospital. High IQ of study participants may be related to the fact that this 
institution is located near several of the country’s top universities. As recruitment of 
cannabis users is often successful at these educational institutions, it is not surprising that 
individuals enrolled in the current studies would exhibit high IQs. Similarly, McLean 
Hospital is located in affluent suburb of Boston which often attracts individuals of higher 
occupational attainment and socioeconomic status. Importantly, intelligence, education 
and occupation attainment are considered proxies of cognitive reserve, a term which 
refers to an individual’s ability to adapt cognitive processes and underlying neural 
networks in the context of brain insult (Stern et al., 2018). As such, individuals with 
higher cognitive reserve would be able to employ compensatory strategies if neural 
processes are negatively impacted by cannabis use. Interestingly, some functional 
neuroimaging studies in cannabis users have demonstrated that even when cognitive 
performance remains intact, altered patterns of brain activation are observed relative to 
healthy controls (Sagar & Gruber, 2018a).  
Results may have also been vulnerable to Type II error given the statistical 
approach used with this moderate sample size. In order to address the fact that raw scores 
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were used for analyses, all cognitive test variables were covaried for age, education, and 
sex. Although it is necessary to control for these variables when raw scores are utilized in 
lieu of normed scores, entering three covariates into a statistical model with moderate 
sample sizes may have led to a failure to detect subtle differences between groups due to 
low statistical power. The potential for Type II error is also compounded by the fact that 
a conservative approach was taken to correct for multiple comparisons. Even though 
numerous research studies have observed poorer cognitive performance on tasks of 
executive function and verbal learning and memory in heavy recreational cannabis users, 
two recent meta-analyses reported only small effect sizes for cannabis-related cognitive 
decrements (Lovell et al., 2019; Scott et al., 2018), suggesting that potential decrements 
may not be detectable in a small sample using a conservative statistical approach.  
It is of note that previous studies of cognition in recreational cannabis users have 
utilized a variety of approaches when examining neuropsychological performance, many 
of which are less stringent than the current approach, while others provide alternative 
options that could be considered for future analyses. For example, Becker et al (2014) 
utilized raw scores adjusted for sex, IQ, and alcohol use, but did not appear to adjust for 
multiple comparisons. Fontes et al. (2011) also utilized raw scores but did not adjust for 
covariates. Further, like the current study, the authors only examined select 
neuropsychological variables based on previous literature and a priori hypotheses. As a 
result of this more targeted approach, however, Fontes and colleagues stated that they 
chose not to correct for multiple comparisons. Some studies, such as Medina et al. (2007) 
have utilized pre-existing neuropsychological test batteries which generate standardized 
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scores; this ensures that all scores are adjusted in the same way (e.g., age- and sex-
corrected, or age- and education-corrected). The current study employed a customized 
selection of cognitive tasks, several of which have different methods of generating 
normed scores; these differences limited the ability to utilize available standardized 
scores from each test. An alternative approach that is often used when examining a 
variety of tests is the use of composite scores. Although this method could be considered 
for future studies and analyses, it is important to recognize that composite scores can be 
calculated using a number of different theoretical approaches (e.g., data-driven or based 
on existing theories of neuropsychological constructs). Importantly, for whichever 
approach is chosen, it is vital to ensure that the composites created actually reflect the 
construct of interest (Jonaitis et al., 2019); otherwise, the composite score is not 
considered valid.  
 No significant between-group results were detected following the conservative 
Bonferroni correction approach. However, the results which were significant prior to 
correction bear some discussion. First, cannabis users overall had fewer correct responses 
on CVLT Trials 1-5, which is consistent with the a priori hypothesis of poorer cognitive 
performance in cannabis users relative to healthy controls. Interestingly, although it was 
predicted that early onset users would demonstrate decrements relative to healthy 
controls and late onset users, the significant results observed prior to Bonferroni 
corrections indicated poorer performance on CVLT Trials 1-5 in the late onset users. 
Despite the fact that these findings were ultimately not statistically significant between 
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the two groups, this potential pattern raises important considerations for future 
investigations if similar findings are observed.  
Previous research has demonstrated that cognitive decrements are largely 
attributed to those with earlier onset of cannabis use, likely related to 
neurodevelopmental vulnerabilities (Battisti et al., 2010; Dahlgren et al., 2016; Fontes et 
al., 2011; Gruber, Sagar, Dahlgren, Racine, et al., 2012; Jacobus et al., 2009; Sagar et al., 
2015; Schneider, 2008). In the current study, it is important to acknowledge that cananbis 
users were divided into two discrete groups using age 16 as a cut-off score. This 
threshold is often employed when examining the impact of early versus late onset 
cananbis use (Ehrenreich et al., 1999; Kempel et al., 2003) and is also consistent with 
previously published data using subsets of the current sample (Dahlgren et al., 2016; 
Gruber, Dahlgren, et al., 2012; Gruber, Dahlgren, Sagar, Gonenc, & Lukas, 2014; 
Gruber, Sagar, Dahlgren, Racine, et al., 2012; Gruber et al., 2011; Sagar et al., 2015). 
However, given that neuromaturation occurs throughout the second and into the third 
decade of life (Giedd et al., 1999; Gogtay et al., 2006; Lebel & Deoni, 2018; Sowell, 
Thompson, Tessner, & Toga, 2001), evidence suggests that regular exposure to cannabis 
during adolescence and throughout emerging adulthood is likely to confer cognitive 
decrements (Lisdahl, Gilbart, Wright, & Shollenbarger, 2013). The average age of 
cannabis onset within the late onset group was approximately 17 years old, with only 
three participants having initiated regular cannabis user after age 21, and all having 
initiated by age 23. It is therefore possible, and even likely, that even those defined as 
“late onset” users in this study are still vulnerable to the effects of cannabis. It is also 
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likely that a relationship between earlier age of onset and poorer cognition may be 
observed if participants with a wider age range of cannabis onset are included in future 
studies (e.g., examining differences between those who initiated use in adolescence as 
well as those who initiated use in later adulthood).  
 In addition, potential decrements noted specifically in the late onset cannabis 
users would also be unexpected in the current study given that few statistically significant 
differences in patterns of cannabis use were observed between early and late onset users 
for the majority of variables measured (episodes of use/week, duration of cannabis use, 
urinary THC levels). Moreover, the early onset users tended to use cannabis more 
frequently (although not statistically significant) and used significantly higher amounts. 
Specifically, early onset users reported using 1.3 times more frequently (19.72 vs. 14.90 
episodes of use/week) and almost twice as much cannabis (10.81 vs. 5.67 grams/week) 
compared to late onset users.  Therefore, it could be posited that factors other than 
frequency and amount of cannabis used may mediate the impact of cannabis on 
cognition.  
Exploratory, hypothesis-generating analyses assessing the relationship between 
urinary THC levels and cognitive performance revealed a significant correlation between 
higher urinary THC levels and slower Trails B completion times (r(46)=.37, p=.01). In 
the context of previous studies which have shown that THC has a dose-dependent 
relationship on cognitive performance (Kowal et al., 2015; Morgan et al., 2012; 
Ramaekers et al., 2006), this relationship provides additional, yet very preliminary, 
evidence that exposure to individual cannabinoids, namely THC, is critical to consider. 
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Accordingly, exposure to individual cannabinoids should be quantified in future studies 
of cannabis and cognition.  
For the current study, cannabinoid exposure, specifically the amount of THC 
contained in actual products used was not directly assessed via laboratory analyses for the 
vast majority of participants. Interestingly, however, a small dataset gathered as a pilot 
arm of this study has revealed that some participants, particularly those recruited most 
recently, reported use of high potency cannabis and/or cannabis concentrates. 
Concentrates (e.g., dabs, wax, shatter, budder, kief) are extremely potent cannabis 
products that have gained popularity in more recent years (Sagar et al., 2018). Some 
studies analyzing THC levels in concentrate products indicate average THC levels of 60-
70% (Raber, Elzinga, & Kaplan, 2015; Smart, Caulkins, Kilmer, Davenport, & Midgette, 
2017), while other studies have shown that levels can reach up to 75-80% (Stogner & 
Miller, 2015). Anecdotally, dispensaries frequently sell products with even higher 
potencies listed on packaging (>90% THC). In addition, the average potency of cannabis 
flower has also increased dramatically in recent years, raising the possibility that some 
cannabis users are exposed to much higher amounts of THC than others. Data from 11 
samples of participants’ cannabis flower products submitted in 2016-2017 to an outside 
laboratory for cannabinoid quantification demonstrated that THC potency ranged from 
11.37-24.35%, with an average of 17.93%. This average is consistent with national 
estimates of cannabis flower potency (17.10% in 2017), which Chandra and colleagues 
(2019) notes represents a significant increase in THC levels relative to prior years, 
including only three years earlier when estimated average potency for cannabis flower 
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was 11.85%. Further, 3 of 17 early onset users (17.65%) and 5 of the 21 late onset users 
(23.81%) in this study specifically endorsed the used of concentrate products. Two 
patients also supplied concentrate products (wax and shatter) for cannabinoid 
quantification; average potency of these products was 68.03% THC (range: 58.45-
77.60%). In addition, preliminary analyses examining cognition in a small pilot group of 
healthy controls, cannabis flower users, and cannabis concentrate users also revealed 
interesting patterns. Specifically, on tests of executive function (Stroop Color Word Test 
and the Trail Making Test) and verbal fluency (Controlled Oral Word Association Test), 
cannabis flower users performed more poorly than healthy controls and, moreover, 
concentrate users performed more poorly than both healthy controls and those who use 
only cannabis flower products. These patterns support previous data suggesting that 
cognitive decrements in cannabis use are related to the negative impact of THC on 
cognition – particularly at higher doses (Kowal et al., 2015; Morgan et al., 2012; 
Ramaekers et al., 2006).  
Cannabis users in the current study did not display significant cognitive 
performance deficits relative to non-cannabis users; however, it is important to note that 
study participants included in the current analyses were recruited for three studies 
between 2003-2019. Thereore, it is likely that across participants, THC potency varied 
significantly and a subgroup of participants with use of more potent THC products may 
have exhibited poorer performance if they were specifically identified and compared to 
healthy controls and/or cannabis users with use of more traditional, lower potency 
 
46 
products. Given current trends regarding the use of higher potency cannabis, future 
studies of cannabis users may be more likely to detect cognitive performance deficits. 
Limitations and Future Directions 
Results must be considered in the context of several limitations. As previously 
noted, the statistical approach utilized in the current study was conservative in terms of 
adjustment for multiple comparisons. Future analyses should explore the use of more 
advanced, General Linear Modeling, approaches, especially given the inherent 
complexities of assessing cannabis use (frequency, amount used, potency, individual 
cannabinoid exposure) as well as the potential interplay between cannabis and a number 
of important demographic variables. These statistical models, particularly when coupled 
with larger sample sizes, could also help address whether additional potential confounds, 
several of which were assessed but not controlled for in the current study (e.g., alcohol 
use or impulsivity), impact cognition. On the other hand, given that higher alcohol use 
and impulsivity are typically associated with poorer cognitive performance, it is unlikely 
that these variables impacted overall study findings. However, it is possible that 
additional factors not assessed in the current study could have influenced results.  For 
example, socioeconomic status, occupational attainment, history of contact sports 
involvement and subconcussive injuries, or genetic factors, could have impacted study 
findings. 
It is also of note that results may not be generalizable to all populations of 
cannabis consumers. In addition to those who may have lower IQ or education (and thus 
potentially lower cognitive reserve), results may also not be generalizable to those with 
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light or casual cannabis use. In the current study, recreational users were required to use 
cannabis at least 4 times per week and reported about 17 uses/week on average. Although 
it would seem intuitive that less frequent users would experience less significant 
cognitive deficits due to lower exposure to cannabinoids, it may also be possible that 
light users are not as habituated to cannabinoid exposure as heavy users. Accordingly, 
recent cannabis use in light users may lead to a change in their typical homeostasis that 
could lead to more marked cognitive consequences. For example, a number of studies 
have found that those who are cannabis naïve exhibit more significant cognitive and 
behavioral changes after THC administration relative to those with previous cannabis 
exposure (Colizzi et al., 2018; Cortes-Briones et al., 2015; Ramaekers, Kauert, 
Theunissen, Toennes, & Moeller, 2009), and those who have used cannabis more recently 
display more significant changes than those who have been abstinent for longer periods 
of time (Cortes-Briones et al., 2015). Future studies are needed, however, to specifically 
assess the residual (i.e., non-acute) impact of less frequent cannabis use on cognitive 
outcomes.  
Results of the current study may also not be applicable to those with certain 
medical or psychiatric conditions or disorders. The current sample excluded those with a 
history of psychiatric illness (e.g., mood, anxiety, psychotic, or other substance use 
disorders) as well as those with serious or chronic illnesses. Interestingly, some research 
has shown that cannabis users diagnosed with certain psychiatric disorders, such as 
schizophrenia (Power et al., 2015; Yucel et al., 2012) or bipolar disorder (Braga, Burdick, 
Derosse, & Malhotra, 2012), demonstrate improved cognition relative to non-cannabis 
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users although not all studies have observed such findings (Rabin et al., 2017). In 
addition, those who treat medical conditions with cannabis may choose products with 
vastly different cannabinoid profiles, which is likely to moderate cognitive effects. Those 
who use medically may also derive a clinical benefit from their cannabis use which, in 
turn, may influence cognitive processes as well (see Chapter 3). 
 As previously noted, the current study did not quantify individual cannabinoid 
concentration from actual products used. However, this is a limitation with the majority, 
if not all, observational studies of recreational cannabis users to date, and many studies 
do not assess THC levels at all. In the current study, detailed information was gathered 
about frequency and magnitude of use. Additionally, urinary THC levels, which were 
normalized to creatinine to help control for metabolic differences, were analyzed in order 
to obtain quantifiable information about cannabis use. Further, pilot results described 
above are promising, and future studies will benefit from conducting laboratory analyses 
of all participants’ cannabis products to obtain quantifiable data regarding specific 
cannabinoid concentrations. For example, higher overall exposure to THC could be 
associated with poorer cognitive performance, while exposure to other non-intoxicating 
cannabinoids, including but not limited to CBD, could confer protective effects.  
Conclusions 
No significant differences were observed between healthy controls and heavy 
recreational cannabis users on tasks of executive function and verbal learning and 
memory, despite hypothesizing that cognitive decrements would be observed in the 
cannabis users. Further, no significant differences were observed when the recreational 
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users were stratified into those with early and late onset of regular cannabis use. Null 
findings, which are in contrast to a large body of evidence suggesting decrements in 
cannabis users, particularly those with early onset, may be related to methodological 






Medical Cannabis Use & Cognition 
 As of March 2020, 48 of 50 states in the US have voted for full or partial medical 
cannabis (MC) programs, leaving only two states without legal access to MC products. 
Although decades of research have examined the association between recreational 
cannabis use and cognitive outcomes, a paucity of studies have specifically examined the 
relationship between MC use and cognitive function. Given the inherent differences 
between medical and recreational cannabis use, it is possible that MC patients may not 
exhibit the same pattern of decrements on neuropsychological measures that have 
traditionally been observed in adolescent/emerging adult heavy recreational users (Crean 
et al., 2011; Jacobus & Tapert, 2014; Lisdahl et al., 2014).  
Interestingly, in the very first study to directly assess the impact of MC treatment 
pre- vs. post-MC treatment in patients using “real world” MC products, Gruber and 
colleagues (2016) conducted a pilot study which examined 11 patients at baseline, prior 
to initiating MC use, and reassessed patients after three months of regular MC treatment 
(all patients chose their own products and selected their treatment regimen). As part of a 
larger longitudinal study, patients were administered a neuropsychological test battery 
which included several measures assessing executive function in order to determine 
whether MC patients would exhibit the similar cognitive decrements to those often 
observed in recreational cannabis users. Interestingly, in contrast to the executive 
function decrements typically observed in recreational cannabis users, after three months 
of MC treatment, MC patients exhibited improved performance on the Stroop Color 
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Word Test and Trail Making Test, reflected by increased speed without loss of accuracy. 
In addition, patients completed self-report measures of mood, anxiety, quality of life, 
impulsivity, and sleep. Results suggested that MC patients experienced cognitive 
improvements in the context of moderate improvements symptoms of depression, 
attenuated impulsivity, improved sleep, and better quality of life.  
Recent work conducted by Olla et al (2019) examined the short-term effects of 
delta-9-tetrahydrocannabinol (THC) in 22 MC patients (mean age of 36) at three 
timepoints: at baseline while not intoxicated, immediately after using high THC (20%) 
cannabis products, and several hours later. Although the authors hypothesized poorer 
cognitive performance while intoxicated, study findings revealed stable or improved 
neuropsychological performance across several cognitive domains. This study is limited 
by a lack of a control group and may have been significantly impacted by practice effects 
given that alternate versions of tests did not appear to be utilized and only a short amount 
of time occurred between assessments. It is also of note that this study only examined the 
impact of THC and did not consider the impact of cannabidiol (CBD) or other non-
intoxicating “minor” cannabinoids, which are often present in products used by MC 
patients. Although no additional information beyond THC content was provided, the 
authors reported administration of joints, vapes, and dabs; thus, it appears likely that the 
products administered were full-spectrum, meaning that they contained additional 
cannabinoids which could have influenced results. Nonetheless, given that a number of 
studies have shown decreased cognitive performance after acute cannabis administration 
(Desrosiers, Ramaekers, Chauchard, Gorelick, & Huestis, 2015; Hart et al., 2010; Hart, 
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van Gorp, Haney, Foltin, & Fischman, 2001), results provide further evidence that MC 
patients who use cannabis to relieve medical and/or psychiatric symptoms may not 
experience the same cognitive decrements as in some of those who use cannabis 
recreationally. 
As studies of MC and cognition are in their infancy, additional research is needed, 
especially given that findings in recreational cannabis consumers are likely not directly 
applicable to MC patients as a function of a number of important factors. For example, 
recreational cannabis use is most likely to begin during adolescence and emerging 
adulthood (Substance Abuse and Mental Health Services Administration, 2019), during 
which critical neurodevelopmental changes occur (Casey et al., 2005; Giedd et al., 1999; 
Gogtay et al., 2006; Houston et al., 2014; Lebel & Deoni, 2018; Sowell et al., 2001). In 
contrast, the majority of MC patients initiate use as adults; MC patients may therefore be 
less vulnerable to exogenous influences, including cannabis. 
Further, if MC treatment is effective at reducing physical or psychological 
symptoms, it is also possible that cognitive function may not be negatively impacted, or 
may even improve, in the context of patients feeling better. For example, chronic pain, 
the most common indication for MC use (Park & Wu, 2017), has been shown to 
adversely impact cognitive performance, specifically on tasks requiring attention and 
executive function (Moriarty, McGuire, & Finn, 2011). Accordingly, cognition may 
improve if patients experience a reduction in pain-related symptoms secondary to MC 
treatment. Research has also demonstrated that sleep quality is associated with cognitive 
functioning; good sleep quality promotes better cognitive functioning and protects against 
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age-related cognitive decline and dementia (Minakawa, Wada, & Nagai, 2019; Scullin & 
Bliwise, 2015; Shi et al., 2018; Spira, Chen-Edinboro, Wu, & Yaffe, 2014). In addition to 
physical symptoms, it is also possible that alleviation of psychiatric symptoms as a 
function of MC use may be an important moderating factor. In a previous study utilizing 
ecological momentary assessment (EMA) to examine mood and cognition in patients 
with bipolar disorder, results revealed that those who used cannabis regularly report 
improvement in clinical symptoms within four hours of smoking cannabis (Gruber, 
Sagar, Dahlgren, Olson, et al., 2012; Sagar et al., 2016). Moreover, the cannabis-using 
patients performed similarly to patients with bipolar disorder who did not use cannabis on 
measures of cognitive performance. Further, studies have demonstrated that anxiety, one 
of the most common indications for MC treatment (Grella, Rodriguez, & Kim, 2014), 
often interferes with both attention and executive function (Vytal, Cornwell, Letkiewicz, 
Arkin, & Grillon, 2013). Certain cannabinoids, particularly CBD, appear to have 
anxiolytic properties as demonstrated by acute administration studies in both healthy 
volunteers (Zuardi, Cosme, Graeff, & Guimaraes, 1993) and individuals with anxiety 
disorders (Bergamaschi et al., 2011). A large case series also reported a 79% 
improvement in retrospective anxiety ratings after one month of CBD treatment 
(Shannon, Lewis, Lee, & Hughes, 2019). MC treatment could therefore result in better 
concentration and enhanced cognitive performance if symptoms of anxiety are reduced. 
In order to more thoroughly examine the impact of MC treatment on cognition, 
the current study built upon up the previous pilot investigation (Gruber et al., 2016), 
which utilized a pre- vs. post-treatment, longitudinal design where MC patients 
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completed baseline assessments prior to initiation of MC use and were reassessed at 
multiple time points after initiation of MC treatment. In the current study, additional 
participants enrolled for longer periods of time (up to 12 months) were included in the 
current analyses. All patients were administered a comprehensive neuropsychological test 
battery, which contained the executive function measures previously reported as well as 
additional measures assessing verbal learning and memory. However, select variables 
were chosen for these preliminary analyses based on a priori hypotheses: Stroop 
Interference Time, Trails B Time, Wisconsin Card Sorting Test (WCST) Categories, 
WCST Perseverative Errors, Letter Number Sequencing, Phonemic Fluency, Rey 
Auditory Verbal Learning Test (RAVLT) Trials 1-5 Correct, RAVLT Short Delay, and 
RAVLT Long Delay. Each of these task variables are described in the Methods section 
below. Participants also completed self-report ratings related to physical and mental 
health (e.g., overall mood, symptoms of depression and anxiety, sleep quality, quality of 
life). Information regarding MC treatment regimens including frequency of use and 
exposure to THC and CBD were also quantified in order to determine if certain MC use 
variables contribute to cognitive and clinical changes. 
Hypotheses 
 Based on pilot work as well as the fact that MC patients are often older and more 
often choose non-intoxicating products or those with more varied cannabinoid profiles, it 
was hypothesized that MC patients would experience improvements in cognitive function 
and ratings of physical and mental health after initiation of MC treatment. Exploratory 
analyses to aid in hypothesis-generation were also planned to provide preliminary data 
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about whether any observed changes in cognitive function or self-report ratings may be 
related to cannabinoid use (e.g., frequency of MC use, THC exposure, or CBD exposure. 
Methods 
Participants 
Data from this study were derived from an ongoing observational, longitudinal 
study led by Dr. Staci Gruber at McLean Hospital in Belmont, MA and funded by private 
donors, foundations, and unrestricted gifts to the Marijuana Investigations for 
Neuroscientific Discovery (MIND) program at McLean Hospital.  
To be considered for study entry for the longitudinal study, participants had to be 
21 or older and either have a valid certification for MC or report a desire to use hemp-
based products, which are currently federally legal and do not require MC certification. 
These criteria were employed in an attempt to enroll only participants who are interested 
in using cannabis exclusively for medical purposes, and to limit recreational use of 
cannabis in the current sample. MC patients could plan to use MC for a variety of 
indications, such as chronic pain, anxiety, mood, sleep, or other medical/psychiatric 
conditions. In addition, MC patients must not have begun regular MC treatment prior to 
baseline assessments. Specifically, participants were either required to be cannabis naïve 
or, if they reported a history of recreational cannabis use, had to report abstinence for one 
year or more to limit the effects of recent cannabis exposure. To help confirm this entry 
criterion, all patients were required to test negative for urinary THC metabolites at 
baseline. Participants also completed the two-factor version of the Wechsler Abbreviated 
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Scale of Intelligence (WASI) (Wechsler, 1999), which provides an estimate of overall 
cognitive functioning, to ensure an estimated IQ of 75 or higher.  
To date, 54 MC patients have been successfully enrolled and have completed at 
least one follow-up assessment over the course of 12 months of MC treatment (follow-up 
visits at 3 months, 6 months, 12 months). A schematic summarizing the study status of 
participants is provided in Figure 3.1. Of the 54 MC patients included in the current 
analyses, 51 patients completed a 3-month follow-up, 43 completed a 6-month follow-up, 
and 30 returned after 12 months. Additional examination of the data releveled that, of the 
54 patients, 28 completed all four visits. Six patients missed an interim visit (1 of these 6 
patients missed 2 interim visits), but all completed baseline and 12-month follow-ups. 
Ten participants are currently “in progress” as they remain enrolled but are awaiting their 
next follow-up timepoint. Ten patients were discontinued or withdrew from the study 
because they either stopped MC use (n=3) or were lost to follow-up (n=7). Of those who 
were lost to follow-up, three indicated that they discontinued for reasons unrelated to MC 
treatment; however, four individuals stopped responding to study staff and no 
information about the reason for discontinuation could be gathered. See Statistical 
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Upon arrival, study procedures were thoroughly explained, and all participants 
were required to read and sign an informed consent form approved by the Partners 
Institutional Review Board. Prior to initiating MC treatment, all enrolled participants 
completed a neuropsychological test battery as well as measures of overall mood state, 
symptoms of depression, symptoms of anxiety, sleep, and quality of life. Following three, 
six, and twelve months of regular MC treatment, participants returned for follow-up visits 
and repeated all study measures (with the exception of the WASI, which was only 
administered at baseline to generate an estimated IQ). For this study, participants 
completed the two-factor version of the WASI in which the Vocabulary and Matrix 
Reasoning subtests are administered. Raw scores for each of these measures are 
transformed into T-scores based on each participant’s age; T-scores are then summed, 
which generates a standardized IQ estimate. 
The neuropsychological test battery was specifically designed to assess executive 
function and memory, as these domains appear to be most vulnerable to cannabis use, 
based on studies of recreational users (Sagar & Gruber, 2018b). In order to examine 
various aspects of executive function, all participants completed the Stroop Color Word 
Test, Trail Making Test, Wisconsin Card Sorting Test (WCST), Letter-Number 
Sequencing (LNS) subtest of the Wechsler Adult Intelligence Scale - Revised (WAIS-R), 
and a phonemic fluency task. In addition, verbal learning and memory was assessed using 
the Rey Auditory Verbal Learning Test (RAVLT). 
 
59 
The Stroop Color Word Test (MacLeod, 1991) is a widely used measure of 
executive function, which contains three conditions in order to assess the ability to inhibit 
an automatic, overlearned response. The first two conditions prime the individual for the 
Interference condition, which is considered the executive function component of the task. 
During the Interference condition, color words are printed in an incongruous ink color 
(i.e., red printed in green, or blue printed in red), and participants must inhibit the natural 
tendency to read the words and instead name the color of the ink. Performance was 
assessed by interference completion times; lower numbers (i.e., faster times) are 
indicative of better performance (MacLeod, 1991). 
The Trail Making Test is comprised of two timed conditions (Lezak et al., 2012). 
While Trails A measures psychomotor speed and attention (participants connect a series 
of numbered circles), Trails B utilizes an alternative set-shifting demand to measure 
cognitive flexibility (participants alternate between connecting numbers and letters). 
Performance on this task was measured by the time to complete Trails B. Three versions 
of the Trail Making Test were rotated across visits to minimize practice effects (Wagner, 
Helmreich, Dahmen, Lieb, & Tadic, 2011). Maximum time allowed is for Trails B is 180 
seconds; lower numbers (i.e., faster times) indicate better performance.  
The WCST is considered a gold standard measure of executive functioning, which 
focuses on cognitive flexibility and set-shifting (Berg, 1948; Lezak et al., 2012). For this 
study, all participants completed the WCST:CV4, a computerized version of the task 
(Heaton & PAR Staff). For this task, participants are to match 64 cards based on sorting 
rules that change throughout the task; participants must utilize feedback (e.g., “correct” 
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or “incorrect”) to adjust to the changing set demands. Primary variables for analyses 
included categories completed (higher numbers are better and can range from 0-6) and 
number of perseverative errors (lower numbers are better). 
The Letter-Number Sequencing (LNS) test (Wechsler, 1987) is also considered a 
measure of executive function, specifically working memory abilities. For this task, the 
examiner reads increasingly longer strings of numbers and letters, and participants are 
asked to re-sequence the string of characters by repeating the numbers in order, followed 
by the letters in alphabetical order. At every other visit, an alternate version was 
presented in which the strings of numbers and letters from the original task were 
presented in reverse order. The total number of correct trials serves as the primary 
outcome variable.  
The Phonemic Fluency task was also utilized to assess executive function. During 
this task, participants must generate as must words as they can that begin with a given 
letter; they are given three letters and for each letter must generate as many words as 
possible within a 60 second timeframe. Alternate versions were utilized at each visit 
(FAS, BHR, PRW, CFL) (Strauss, Sherman, & Spreen, 2006). The number of unique 
words generated for all three letters is calculated, and higher scores reflect better 
performance. 
Verbal learning and memory was assessed with the Rey Auditory Verbal 
Learning Test (RAVLT) (Schmidt, 2016). For this task, the examiner reads a 15-item 
word list, and participants must recall as many words as they can. The word list is 
presented over the course of five trials; overall learning is reflected by the total number of 
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words remembered across all five trials. Memory for the list is then assessed immediately 
after presentation of a distractor last (Short Delay) and re-assessed after a 20-minute 
delay (Long Delay). Alternate word lists were utilized at each visit to minimize practice 
effects (Crawford, Stewart, & Moore, 1989; Geffen, Butterworth, & Geffen, 1994; 
Majdan, Sziklas, & Jones-Gotman, 1996). For total correct responses over Trials 1-5, the 
maximum score is 75, and for both short and long delay variables the maximum score is 
15; higher scores equate to better task performance. 
To determine if patients experienced any clinical changes (e.g., mood, anxiety 
sleep, quality of life) related to MC use, which could also potentially impact cognitive 
performance, all MC patients completed a battery of clinical rating scales at each visit. 
Specifically, participants completed scales assessing various aspects of mood, including 
the Profile of Mood State (POMS) (Pollock, Cho, Reker, & Volavka, 1979) and the Beck 
Depression Inventory (BDI) (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961). MC 
patients also completed the Beck Anxiety Inventory (BAI) (Beck & Steer, 1990), State 
Trait Anxiety Index (STAI) (Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983); 
Pittsburgh Sleep Quality Index (PSQI) (Buysse, Reynolds, Monk, Berman, & Kupfer, 
1989), and a questionnaire reflecting quality of life (Short Form 36 Health Survey 
Questionnaire [SF-36]) (Ware & Sherbourne, 1992).  
The POMS is comprised of 65 adjectives commonly used to describe mood states. 
Individuals are asked to indicate how they feel at that moment in relation to each of the 
adjectives using a five-point scale ranging from “not at all” (0) to “extremely” (4). The 
POMS consists of 6 subscales, which measure vigor, anger, depression, confusion, 
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tension, fatigue, and depression. These scores are used to calculate an overall composite 
score of Total Mood Disturbance (TMD). TMD = (anger + confusion + tension + fatigue 
+ depression) – vigor. TMD scores can range from -32 to 200; lower scores are 
considered better as they reflect lower levels of mood disturbance.  
The BDI is a 21 item-self-report measure that can be used to assess the severity of 
depression and is one of the most widely-used measures to assess symptoms related to 
depression. Each item on the BDI relates to a symptom of depression and is rated by the 
subject using a 0-3 scale; total scores can range from 0-63 where higher scores reflect 
higher levels of depressive symptomatology (i.e., lower scores are better). Generally, 
scores of 0-9 represent no or minimal depression, 10-18 represent mild depression, 19-29 
represent moderate depression, and 30 or higher represents severe depression (Beck, 
Steer, & Garbin, 1988). 
The BAI is a 21 item-self-report measure of anxiety that assesses subjective, 
somatic, and panic-related symptoms of anxiety. Each item on the BAI is rated on a scale 
of 0 to 3, and is descriptive of subjective, somatic, or panic-related symptoms of anxiety. 
Total scores range from 0-63. BAI scores of 0 to 7 are classified as minimal anxiety, 8 to 
15 reflects mild anxiety, 16-25 denotes moderate anxiety, and 30 or more is considered 
severe anxiety (Beck & Steer, 1990). 
The STAI form is comprised of two 20-item scales that measure the more 
temporary condition of “state” anxiety and the more general and long-standing quality of 
“trait anxiety.” For each scale, each item is scored on a scale that ranges from 0  to 4, and 
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total scores for each range from 0-80 (higher scores indicate higher levels of either state 
or trait anxiety). 
The PSQI assesses current sleep quality and disturbance. This scale queries 
aspects of subject sleep quality, sleep latency, sleep duration, habitual sleep efficiency, 
sleep disturbances, use of sleeping medication, and daytime dysfunction, which are then 
summed to generate a global score. Scores range from 0-21 where a score of 0 indicates 
no disturbance and score of 21 would reflect severe sleep difficulties in all areas. As 
such, lower scores indicate better sleep.  
The SF-36 is a multi-purpose, short-form health survey that gives an 8-scale 
profile of functional health and well-being scores: 1) Physical Functioning (limitations in 
normal role/work activities due to physical health); 2) Role Limitations: Physical Health 
(limitations in usual physical activities); 3) Role Limitations: Emotional Problems 
(limitations in activities because of emotional problems); 4) Energy/Fatigue (vitality); 5) 
Emotional Well-Being (psychological distress and mental health); 6) Social Functioning 
(limitations in social activities); 7) Pain (severity and the degree to which pain affects 
quality of life by interfering with normal work); and 8) General Health (perceptions about 
one’s health). On the SF-36, each scale is scored from 0-100 where 0 is considered 
“completely dysfunctional” and 100 is “no dysfunction.” Accordingly, higher scores 
indicate better quality of life.  
After the completion of their baseline visit, MC patients were asked to use either 
paper-and-pencil or electronic drug diaries (based on patient preference) to track their 
MC use once they began using MC regularly. Between visits, they were also contacted by 
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phone for monthly check-in visits to corroborate drug diary entries, which included 
information about product type (e.g., flower, cartridge/pod, solution/tincture, edibles, 
capsules, topicals), number of MC episodes, amount of MC used, mode of use (e.g., 
smoke, vape, ingest, sublingual, cutaneous) via a timeline follow-back procedure (TLFB; 
Sobell et al., 1998) and additional follow-up queries tailored to MC treatment. To gather 
information about cannabinoid constituent levels in each product, information was 
collected from product labels and certificates of analyses posted on product websites. 
Each participant was also asked to provide a sample of his/her most frequently used MC 
product(s) to be analyzed by an outside laboratory (ProVerde Laboratories, Inc.) for 
cannabinoid constituent profiling. Although information was gathered about a wide range 
of cannabinoids, specific focus was placed on THC and CBD, the primary intoxicating 
and non-intoxicating constituents, respectively. A standard metric of cannabinoid use, 
measured in milligrams (mg) of THC and CBD used per week, was then calculated for all 
patients using available data from laboratory-based data, drug diary entries, and 
information gathered via the modified TLFB (see Appendix A).  
MC patients also provided information for conventional medications used at least 
weekly, including the name of the medications, indication for use, frequency, and dose. 
Medications were then sorted into categories (opioids, benzodiazepines, antidepressants, 
anti-inflammatories, over-the-counter analgesics, etc.), and mg/week of medications used 
was closely tracked and recorded according to drug type. Given the various medications 
reported and small sample sizes for each drug class, only baseline medication is reported 




Descriptive statistics (e.g. mean, standard deviation, median, and range) were 
calculated for demographic and MC use variables. As not all patients included in the 
current analyses completed all four study timepoints, those with missing data were 
divided into two discrete groups: 1) data missing at random (MAR; n=47) and 2) 
unknown whether data were MAR (n=7). Data were considered MAR for MC patients 
who completed the study but had missed a visit(s), enrolled individuals who are still 
considered “in progress,” and those who reported withdrawing from the study due 
reasons unrelated to MC use. For those who stopped MC treatment or were lost to 
follow-up for unknown reasons, analyses were conducted to determine whether missing 
data could be considered MAR. Specifically, changes in self-report ratings of MC 
treatment outcomes (e.g., mood, anxiety, sleep, and quality of life) between baseline and 
3 months were compared between 1) those who remained enrolled throughout the 12-
month timepoint, are “in progress,” or withdrew from the study for reasons unrelated to 
MC use and 2) those who stopped using MC or were lost to follow-up for unknown 
reasons. As no significant between-group differences emerged for any of these variables, 
it was determined that data were MAR. Accordingly, imputation for missing data was 
conducted using last observation carried forward (LOCF) for those who were in progress, 
stopped using MC, or lost to follow-up. For the six participants with missed interim 
visits, missing data for these visits were imputed by taking an average of scores from the 
visits preceding and following the missed timepoint(s) for each variable.    
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Repeated measures analyses of covariance (rmANCOVAs) were used to assess 
within-subject changes from baseline to follow-up visits for cognitive and self-reporting 
rating scales. For all analyses, raw scores were utilized for cognitive performance data 
and self-report ratings. However, rmANCOVAs controlling for age, sex, and education 
were conducted for the cognitive data, and rmANCOVAs controlling for age and sex 
were performed for the self-report rating scales. In cases where the rmANCOVA yielded 
significance, additional rmANCOVAs were utilized to compare baseline data to each 
follow-up  (e.g., baseline vs. 3 months, baseline vs. 6 months, and baseline vs. 12 
months); results from each of these analyses are reported with effect sizes (partial eta 
squared) and 95% confidence intervals based on estimated marginal means. All analyses 
of cognitive performance were Bonferroni-corrected: α≤.05/6=.008 for variables in the 
executive function domain (Stroop Interference Time, Trails B Time, WCST Categories 
and Perseverations, LNS, and Phonemic Fluency), and α<.05/3=.017 for variables in the 
verbal learning and memory domain (RAVLT Trials 1-5, Short Delay, and Long Delay). 
Similarly, clinical ratings scales were also Bonferroni-corrected: α≤.05/2=.025 for 
measures of mood (POMS TMD, BDI), α≤.05/3=.017 for measures of anxiety (BAI, 
State Anxiety, Trait Anxiety), and α≤.05/8=.006 for the 8 SF-36 subscales. As only one 
scale (PSQI) was used to assess sleep, no correction was utilized for this domain. 
As previously noted, in order to assess whether MC use variables impacted 
outcomes measures, standard metrics of THC and CBD exposure were calculated for 
each participant at all follow-up visits using information from laboratory analyses, 
certificates of analyses, and product labels. Partial correlation analyses (2-tailed) 
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covarying for age, sex, and education were used to assess the relationship between 
cannabinoid exposure (THC and CBD mg/week) and changes in cognitive performance 
and self-report ratings. For these correlations, data from comparisons of baseline to 3 
months were utilized; as 51 of 54 patients completed this visit, this timepoint contained 
the fewest imputed data points. 







  Baseline 
  3 months 
  6 months 
  12 months 
Cognition 
  Stroop Interference Time 
  Trails B Time 
  WCST Categories 
  WCST Perseverative Errors 
  LNS 
  Phonemic Fluency 
  RAVLT Trials 1-5 Correct 
  RAVLT Short Delay 







  Baseline 
  3 months 
  6 months 
  12 months 
Rating Scales 
  POMS 
  BDI 
  BAI 
  STAI 
  PSQI 
  SF-36 
Partial correlations   Age 
  Education 
  Sex 
MC Use  
  Episodes/week 
  THC mg/week 
  CBD mg/week 
 Rating Scales 
   POMS 
   BDI 
   BAI 
   STAI 
   PSQI 
   SF-36 
Table 3.1 Chapter 3: Statistical Analyses Overview 
Results 
Demographics 
At the time of analysis, 54 MC patients (20M, 34F) had completed a baseline visit 
and returned for at least one follow-up visit. MC patients were between the ages of 22-78 
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and reported an average of 23.57 years (range 3-47) of abstinence from regular 
recreational cannabis use; see Table 3.21. MC patients used MC to treat a variety of 
symptoms and conditions, including pain (n=33), anxiety (n=31), sleep (n=22), mood 
(n=14) attention (n=4), and other medical conditions (e.g., gastrointestinal disorders; 
n=4); 36 patients reported using MC to treat more than one condition. In terms of MC 
use, over the course of the one-year study, patients reported using approximately MC 9-
11 times/week on average (see Table 3.3 for specific MC use information at each visit). 
Interestingly, standardized metrics of cannabinoid use revealed that, overall, THC 
exposure (mg/week) was notably lower than CBD exposure (mg/week) at each visit. 
DEMOGRAPHICS (n=54) Mean (SD) Median [Range] 
Sex 20 Male (37.04%) 34 Female (62.96%) -- 
Race 
48 White (88.89%) 
5 Non-White (9.26%) 
1 Prefer Not to Answer (1.85%) 
-- 
Age 49.17 (16.45) 52.5 [22-78]  
Education 16.58 (2.08) 16 [12-21] 
WASI IQ 121.02 (7.54) 120.5 [99-134] 
BASELINE CONVENTIONAL  
MEDICATION USE (mg/week)  
 Opioidsa 200.81 (339.78) 87.50 [1.72-1225.00] 
NSAIDsb 2247.44 (4704.60) 567 [33.60-19600.00] 
Over-the-Counter Analgesicsc 4014.18 (3693.84) 2100 [26.00-9100.00] 
Benzodiazepinesd 12.57 (32.32) 4.50 [0.03-140.00] 
Antidepressantse 835.17 (713.42) 630.00 [70.00-12100.00] 
Mood Stabilizerf 4618.50 (5020.19) 2450.00 [84.00-18900.00] 
Sedativeg 58.08 (53.83) 70.00 [3.45-150.00] 
WASI=Wechsler Abbreviated Scale of Intelligence  
NSAIDs = Nonsteroidal anti-inflammatory drugs 
a n=12, b n=20, c n=7, d n=18, e n=29, f  n=14, g n=11 
Table 3.2. MC Patient Demographics. 
                                               
1 Although marital and occupation status were collected as part of the study, these data were not accessible 




CANNABIS USE Mean (SD) Median [Range] 
Duration of cannabis abstinence (years)b 23.57 (14.20) 25 [3-47] 
MC Uses/Week    
  Baseline to 3 Monthsa 9.25 (7.91) 7.91 [1.14-30.02] 
  3 Months to 6 Monthsb 10.18 (8.35) 7.0 [0.66-38.50] 
  6 Months to 12 Monthsc 11.60 (8.26) 9.0 [0.75-30.63] 
THC mg/week   
  Baseline to 3 Monthsd 64.48 (186.69) 9.93 [0-1000.50] 
  3 Months to 6 Monthse 43.13 (79.79) 12.07 [0-321.55] 
  6 Months to 12 Monthsf 40.23 (52.43) 19.98 [0-210.92] 
CBD mg/week   
  Baseline to 3 Monthsd 158.04 (290.61) 29.00 [0-1303.99] 
  3 Months to 6 Monthse 204.97 (58.58) 62.73 [0-1434.26] 
  6 Months to 12 Monthsf 99.27 (269.99) 47.25 [0.24-1228.12] 
MC = medical cannabis; THC=delta-9-tetrahydrocannabinol; CBD=cannabidiol  
a n=52, b n=46, c n=28, d  n=38, e n=32, f n=21 
Table 3.3. Medical Cannabis/Cannabinoid Use. 
 
Cognitive Performance 
Over the course of one year of MC treatment, patients did not exhibit any 
significant changes across measures executive functioning or verbal learning and memory 
after correcting for multiple comparisons (see Table 3.4). Importantly, although 
significant improvements were not noted on any measure, no significant declines in 






(N=54) Baseline 3 Months 6 Months 12 Months rmANCOVA 
Task 
Variable Mean (SD) Mean (SD) Mean (SD) Mean (SD) F p (η
2) 
Executive Function   
Stroop Interference Time (sec) 105.30 (25.32) 98.06 (24.89) 94.91 (23.55) 93.37 (22.94) 2.89 .05 (.05) 
Trails B (sec) 60.15 (17.58) 55.94 (15.41) 65.56 (26.62) 63.85 (28.46) 0.33 .80 (.01) 
WCST Categories 3.06 (1.43) 3.31 (1.41) 3.58 (1.40) 3.52 (1.54) 1.20 .31 (.02) 
WCST Perseverative Errors 9.17 (6.17) 8.83 (7.22) 8.21 (6.71) 7.83 (6.49) 0.77 .51 (.02) 
LNS 11.93 (2.57) 12.91 (2.89) 12.88 (3.35) 12.93 (3.57) 0.28 .84 (.01) 
Phonemic Fluency 49.57 (13.89) 48.73 (13.70) 51.27 (14.34) 50.13 (13.48) 0.76 .52 (.02) 
Verbal Learning and Memory    
RAVLT Trials 1-5  Correct 51.15 (8.69) 49.97 (8.24) 52.43 (8.39) 51.76 (8.74) 0.21 .89 (<.01) 
RAVLT Short Delay 10.78 (3.01) 10.44 (2.70) 10.95 (2.79) 10.96 (2.79) 0.65 .58 (.01) 
RAVLT Long Delay 10.80 (3.16) 10.34 (2.96) 10.67 (2.91) 10.50 (3.05) 0.82 .49 (.02) 
rmANCOVAs were not significant after Bonferroni corrections: p≤.05/6=.008 for Executive Function tasks, and p<.05/3=.017 for Verbal 
Learning & Memory tasks. Results that were significant before Bonferroni corrections are italicized.  
Degrees of freedom (df)=1,50  
Table 3.4 Changes in Performance on Tasks of Cognitive Function Over the Course of 3, 6, and 12 Months of MC Treatment 
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Self-Report Ratings of Mood, Anxiety, Sleep, and Quality of Life 
Ratings of current mood state as well as symptoms of syndromal depression and 
anxiety are reported in Table 3.5. On the POMS, patients exhibited significantly 
decreased scores. Follow-up analyses indicated that TMD was significantly decreased at 
after 3 and 12 (but not 6) months of MC treatment relative to baseline. Overall, 
significant improvements were not observed on the BDI.  
On measures of anxiety, BAI scores were significantly reduced, and additional 
comparisons revealed that these reductions were observed at every follow-up visit 
relative to baseline. In addition, significant changes were noted on the on the STAI; both 
state and trait anxiety were significantly lower following 3 and 12 months of MC use, but 
findings did not reach statistically significant levels after 6 months of MC treatment.  
Self-report ratings of sleep and quality of life are reported in Table 3.6. On the 
PSQI, patients reported improved sleep quality. Specifically, lower sleep disturbance was 
observed at all follow-up visits relative to baseline. Quality of life ratings indicated no 
significant improvements overall after Bonferroni corrections. 
Notably, significant worsening of mood, anxiety, sleep, or quality of life was not 
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Beck Depression Inventory (BDI)         
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Beck Anxiety Inventory (BAI Total)         





















State-Trait Anxiety Inventory (STAI)       










































Significant based on the following Bonferroni corrections are bolded: p≤.05/2=.025 for mood scales (POMS TMD and BDI); p<.05/3=.017 for 
anxiety scales. Results that were significant before Bonferroni corrections are italicized. 
Degrees of freedom (df)=1,51  







 Table 3.6. Changes in Self-Reported Sleep Quality and Quality of Life Over the Course of 3, 6, and 12 Months of MC Treatment  
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Pittsburgh Sleep Quality Index (PSQI)         
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Significant results based on the following Bonferroni corrections are bolded: p<.05/8=.006 for quality of life ratings (no correction was used for 
sleep as only a single measure was used). Ratings that were significant before Bonferroni corrections are italicized. 
*Higher score indicates improvement on the SF-36 
Degrees of freedom (df)=1,51  
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Correlations: MC Use vs Self-Report Ratings 
Although correlations were planned between MC use and cognition, no 
significant differences were observed across any measures; therefore, these analyses were 
ultimately not conducted. However, correlation analyses were utilized to examine the 
potential relationship between MC use and changes in self-report ratings between 
baseline and 3 months, as a number of significant improvements were noted on these 
measures. Analyses indicated that improvement on self-reporting ratings were not related 
to frequency of MC use in general, but interesting relationships were revealed when 
specific cannabinoid exposure was assessed. Higher CBD exposure was related to 
improvements in mood as measured by POMS TMD (r(33)=.51, p=<.01) and BDI scores 
(r(33)=.40, p=.02). On scales of anxiety, improvements on STAI state (r(33)=.50, 
p=<.01)  and trait anxiety (r(33)=.51, p=<.01) measures were each related to higher 
levels of CBD exposure. No significant relationship was noted between cannabinoid use 
and BAI ratings. On the SF-36, while improvement on certain subscales was related to 
higher CBD use, for other subscales, higher THC exposure was related to improvements. 
Specifically, Physical Functioning (r(33)=-.36, p=.03), Role Limitations due to 
Emotional Problems (r(33)=-.34, p=.05), and Emotional Wellbeing (r(33)=-.38, p=.02) 
subscales were related to increased CBD exposure, whereas Role Limitations due to 
Physical Health(r(33)=-.38, p=.02), Social Functioning (r(33)=-.42, p=.01), and Pain 










POMS TMD 0.20 0.04 0.51** 
BDI 0.25 0.20 0.40** 
BAI 0.17 0.07 0.21 
BAI 0.17 0.07 0.21 
STAI    
  State Anxiety 0.13 -0.09 0.50** 
  Trait Anxiety 0.21 -0.03 0.51** 
PSQI -0.14 0.25 0.05 
SF-36†    
  Physical Functioning -0.06 -0.09 -0.36** 
  Role Limitations:   
  Physical Health -0.02 -0.38** -0.28 
  Role Limitations: 
  Emotional Problems -0.18 -0.22 -0.34* 
  Energy/Fatigue -0.10 0.02 -0.28 
  Emotional Well-Being -0.16 0.11 -0.38** 
  Social Functioning -0.10 -0.42** -0.26 
  Pain -0.06 -0.52** -0.26 
  General Health 0.07 -0.08 -0.24 
*p<.05 **p<.01  
Df= 45 for MC use; df=33 for THC and CBD mg/week.   
†Reverse scored (improvements are denoted by negative numbers on the SF-36) 





 The current study was designed to extend findings from a previous pilot study 
which reported some improvement on measures of executive function in a small sample 
of 11 patients following three months of MC treatment (Gruber et al., 2016). Updated 
analyses, which examined a larger sample of MC patients over a longer period, utilized 
additional cognitive performance data, and controlled for covariates, did not detect 
significant improvements across measures of cognition over the course of one-year of 
MC treatment. However, a number of significant improvements were noted for self-
report ratings related to mood, anxiety, and sleep. 
These findings, which demonstrate stable cognition in patients after initiation of 
MC use may be considered to be in contrast to previous literature in recreational cannabis 
users that has consistently documented evidence of decrements on measures of executive 
function (Crean et al., 2011; Lisdahl et al., 2014; Sagar & Gruber, 2018b) as well as 
verbal learning and memory (Lisdahl et al., 2014; Sagar & Gruber, 2018b; Schwartz, 
Gruenewald, Klitzner, & Fedio, 1989; Solowij et al., 2011). However, not all studies have 
demonstrated such decrements, including the results presented in Chapter 2. Although 
few other studies have examined cognitive performance in those who use cannabis 
medically, a recent 12-month longitudinal study examined 69 individuals who report 
using cannabis to self-medicate chronic medical conditions (Bouso et al., 2020). This 
study, which utilized a self-report measure of cognition, the Cognitive Failures 
Questionnaire, also found that although no improvements were reported over time, no 
evidence of cognitive deterioration was reported over the course of 12 months. However, 
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as participants were not cannabis-naïve at baseline, this investigation is limited by the 
lack of a cannabis-naïve assessment in addition to the fact that a self-report measure of 
cognition was utilized.  
In the current study, MC patients exhibited significant improvements after 
initiation of treatment across measures of mood, anxiety, sleep. Although quality of life 
improvements were not statistically significant, when examining results prior to 
Bonferroni corrections, findings suggest that some subscales did improve, including pain 
and social functioning. Although Buoso and colleagues (2020) reported only modest 
improvements in medical symptoms in their study and did not detect significant changes 
in quality of life, it is possible that improvements in that study may not have been 
detected due to several additional methodological differences between studies. 
Importantly, Buoso and colleagues recruited “therapeutic members” of “social cannabis 
clubs” located in in Spain, where formalized medical cannabis programs are not yet 
established. Accordingly, it is quite plausible that participants in that study may not have 
used cannabis solely for medical purposes and may have also used cannabis 
recreationally. Without medical cannabis programs, it is also likely that individuals 
wishing to use cannabis medically had limited access to cannabis products, including 
those containing significant amounts of cannabinoids other than THC, including CBD 
and others posited to have therapeutic benefit.  
Current study findings are also supported by a number of other studies which 
suggest clinical improvements secondary to medical cannabis/cannabinoid use among 
various patient populations. For example, a survey study of California residents found 
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that of the 5% of Californians who reported having tried MC, 92% reported that MC 
helped treat a serious medical condition (Ryan-Ibarra, Induni, & Ewing, 2015). Another 
study of MC patients in Arizona found that, among those who endorsed anxiety 
symptoms, 83% reported “a lot or almost complete relief” from anxiety when using MC 
(Troutt & DiDonato, 2015). In addition to these survey studies, acute administration 
studies, observational studies, a handful of clinical trials, and several reviews have 
reported improvements in medical and psychiatric symptoms secondary to MCs or 
cannabinoid use across a range of conditions and symptoms, including chronic pain 
(National Academies of Sciences, 2017; Pawasarat et al., 2020; Poli, Crestani, Salvadori, 
Valenti, & Sannino, 2018), anxiety (Bergamaschi et al., 2011; Masataka, 2019; Shannon 
et al., 2019; Zuardi et al., 1993; Zuardi et al., 1982), and sleep (Kuhathasan et al., 2019).  
 Several factors likely contributed to the current findings. First, the current study 
represents the first to directly assess the specific impact of THC and CBD on cognition 
and health-related variables (mood, sleep, anxiety, and quality of life) in “real world” MC 
patients, using a quantifiable, standardized metric. On average, MC patients in the current 
study reported higher CBD exposure relative to THC at all follow-up visits, after 
initiation of MC use. As higher amounts of THC are often linked to cognitive decrements 
in recreational cannabis users (Kowal et al., 2015; Morgan et al., 2012; Ramaekers et al., 
2006), and CBD has demonstrated efficacy in mitigating or preventing THC-related 
negative effects on cognition (Englund et al., 2013; Morgan et al., 2012), this overall 
pattern of cannabinoid exposure may have been protective against potential cognitive 
decrements. In addition, correlation analyses, although preliminary, demonstrated that 
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higher CBD exposure was associated with improved mood (POMS TMD, BDI) and 
anxiety symptoms on the STAI. On the SF-36, CBD exposure also appeared to be related 
to measures of mental health, as increased CBD was correlated with improvements on 
scales assessing role limitations due to emotional problems and emotional wellbeing.  
Higher CBD was also related to improvements on the SF-36 physical functioning 
subscale. In terms of THC, correlations revealed higher THC exposure was associated 
with improvements on the SF-36 subscales reflecting role limitations due to physical 
health, pain, and social functioning. Overall, this pattern appears to suggest that CBD 
may confer benefits to aspects related to emotional health (i.e., mood, anxiety, and 
emotional wellbeing), while THC may exert beneficial effects on physical health, 
including pain, and potentially social functioning. However, as these results are 
preliminary, these hypotheses will need to be tested more thoroughly in future studies.  
Limitations  
Results from the current study provide an important foundation for future MC 
research, and while results are promising, findings must be considered in light of several 
limitations. First, the contribution of practice effects cannot be ruled out. Although 
alternate forms of tests were utilized, alternate versions were not available for the Stroop 
and WCST, the latter of which is particularly vulnerable to practice effects. However, it 
is possible that the minimum of 3 to 6-months between administration of cognitive 
measures may have reduced the influence of practice effects. For example, some studies 
have reported no practice effects on the Letter Number Sequencing and Trail Making 
tasks with even weekly administration (Beglinger et al., 2005). In addition, studies noting 
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practice effects on the Stroop test have typically utilized a daily to weekly administration 
schedule (Gul & Humphreys, 2015), which is significantly more frequent than the current 
testing schedule. Even though improvements were not observed, it is possible that 
practice effects could have masked potential decrements that patients could be 
experiencing in their day-to-day cognitive functioning. In order to address this potential 
issue, a study arm has recently been added to allow recruitment of a group of treatment-
as-usual (TAU) patients who have similar conditions but who do not use MC. Once a 
large enough group is recruited, changes in each of these groups can be examined over 
time and in comparison to one another in order to rule out practice effects and directly 
compare MC treatment to conventional treatments. 
  An additional limitation of the current study is the possibility that treatment 
expectancy or the “placebo effect” may have impacted current results. Future MC studies 
should include measures which control for this potential confounding variable by 
assessing the degree to which patients believe MC treatment can positively and/or 
negatively impact symptoms of their medical condition(s), cognition, physical and mental 
health, and quality of life prior to initiation of treatment. Measures to assess MC 
treatment expectancy are currently in development.  
Further, a number of factors beyond treatment expectancy, including the 
underlying reasons why an individual chooses to use or not use MC, could have also 
impacted study findings. For example, the number of conventional treatments or 
medications an individual has tried in the past, efficacy of conventional treatments, 
societal factors or social stigma, and/or affordability and access to MC are all important 
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considerations. Future studies are needed to examine each of these variables. Data 
collected from individuals who transition from the TAU to MC group, as well as 
individuals who cease MC use, could provide critical preliminary information that would 
inform researchers of potential confounds that should be measured and controlled for in 
future investigations. 
Although the current sample size is considered moderate for some analyses, it is 
still too small to control for additional potential covariates. The sample size also limits 
the statistical approaches available; more advanced analyses are planned once larger 
statistical power is attained. In addition, a number of data points are missing; while this is 
primarily due to the fact that many participants are still “in progress,” other patients 
missed visits or were lost to follow-up. Analyses determined that data were missing at 
random, and commonly used imputation methods were there implemented; however, 
drawbacks of mean imputation and LOCF approaches must be acknowledged. Although 
each are relatively straightforward and easily implemented, they greatly reduce the 
variance of the dataset. Further, LOCF assumes that the data will not change over time 
and has the potential to generate data that may not be an inaccurate reflection of the true 
data (Shoop, 2015). Future analyses will benefit from more advanced imputation 
strategies, including multiple or Bayesian imputation, which can help address some of the 
limitations of imputed data. 
Finally, as this is a longitudinal, observational study of MC patients, it is also of 
note that indications for MC use varied widely, and thus conclusions cannot be drawn 
about the efficacy of MC for specific medical conditions. However, results provide an 
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overarching view of the cognitive effects related to MC treatment. Similarly, modes of 
MC use were also somewhat heterogenous across patients, as patients chose different and 
sometimes multiple product types and administration routes. While this information was 
collected, larger sample sizes are needed to clarify how discrete modes of use may affect 
symptom alleviation, alter the onset and duration of therapeutic effects, and ultimately 
impact safety.  
 Future Directions 
In the future, once larger sample sizes are attained, path analyses are warranted to 
further clarify the relationships between variables assessed in this study, including 
cognitive performance, self-report ratings, and overall cannabinoid exposure. In addition, 
studies examining the contribution of potential changes in conventional medication use 
are also important, particularly given the recent attention and focus on the relationship 
between MC use and opioid exposure (Parsons & Hurd, 2015; Piper et al., 2017; Shover, 
Davis, Gordon, & Humphreys, 2019; Takakuwa, Hergenrather, Shofer, & Schears, 2020). 
As epidemiological studies have revealed mixed results, prospective data gathered via 
face-to-face visits, as was done in the current study, will be valuable to assess.     
As previously noted, preliminary data raise the possibility that THC and CBD 
could differentially impact MC treatment outcomes. However, it is also important to note 
that other cannabinoids present in patients’ products may have also impacted study 
findings. Given that laboratory analyses of products quantified 12 cannabinoids, future 
analyses with larger sample sizes will more closely explore the unique contributions of 
individual cannabinoids and combinations of cannabinoids. Clinical trials, which control 
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the dose of individual cannabinoids, will help provide definitive information on each of 
these cannabinoids but are currently difficult given federal restrictions limiting clinical 
trials of cannabis-based products.  
In addition, it is important to assess whether age of the consumer is a moderating 
variable. Unlike most studies of recreational users which assess young adults, often with 
onset of cannabis use in their adolescent years, those enrolled in the current study were 
significantly older (average age of 49). Not only is this important because of the critical 
neurodevelopment that takes place during adolescence, but older adults experience 
marked changes in the endocannabinoid system (ECS) relative to younger individuals. 
For example, preclinical studies have revealed decreased levels of the endocannabinoid 
2-arachidonoylglycerol (2-AG) in the aging mouse brain (Piyanova et al., 2015). Rodent 
studies have also reported that CB1 binding peaks in puberty, remains stable early to 
mid-adulthood, and ultimately declines in older adulthood; human studies have similarly 
revealed higher CB1 receptor binding in younger individuals relative to older adults (Di 
Marzo, Stella, & Zimmer, 2015). In addition, although there is a paucity of studies 
examining cognition secondary to MC use in older adults, several animal studies 
highlight the potential for cannabis to improve cognition in this population (Weinstein & 
Sznitman, 2020), including one study which demonstrated that administration of low-
dose THC reversed age-related decline in older adult mice (Bilkei-Gorzo et al., 2017). 
Although cognitive improvement was not observed in the current study, it is also 
important to acknowledge that cognitive decrements were not observed over time in MC 
 
84 
patients. It is possible that specific formulations designed to address age-related ECS 
changes could yield beneficial effects; however, more research is needed. 
Conclusions 
In a 12-month longitudinal, observational study, patients using MC for various 
medical conditions exhibited stable performance on measures of executive function and 
verbal learning and memory; however, the potential influence of practice effects cannot 
be completely disregarded and must be more fully addressed in future studies and 
analyses. Significant improvements on self-report measures of mood state, depressive 
symptomatology, symptoms related to anxiety, sleep disturbance, and some aspects of 
quality of life were noted after initiation of MC treatment relative to pre-MC use levels. 
Although results could have been influenced by MC treatment expectancies, findings 
extend previous research studies which have observed clinical improvements secondary 
to MC use. However, investigations examining the effects of individual cannabinoids, the 
impact of MC treatment on the use of conventional medications, and age of the consumer 
are warranted in order to elucidate the public health implications associated with MC 
treatment. Ultimately, it will be critical to examine the relationship between these 
variables in order to maximize the therapeutic potential of cannabis while minimizing 




Cannabis Use Disorder 
Cannabis use disorder (CUD) is defined in the Diagnostic and Statistical Manual 
of Mental Disorders – 5th Edition (DSM-5) as “a problematic pattern of cannabis use 
leading to clinically significant impairment or distress,” which is manifested by two or 
more of the following symptoms occurring in a 12-month period: 1) using cannabis in 
larger amounts or over a longer period than intended; 2) persistent desire or unsuccessful 
effort to cut down; 3) spending significant time obtaining, using, or recovering from 
cannabis; 4) failure to meet obligations; 5) using in spite of social/interpersonal problems 
caused or exacerbated by cannabis use; 6) giving up or limiting important activities 
because of cannabis use; 7) using in hazardous situations; 8) use despite 
persistent/recurrent physical or psychological problems that are caused or exacerbated by 
cannabis; 9) tolerance; 10) cravings or desire to use cannabis; and 11) symptoms of 
withdrawal (American Psychiatric Association, 2013). Although there is general 
consensus that the majority of recreational users do not develop CUD, estimated rates of 
CUD are highly variable across studies.  For example, data from two large 
epidemiological survey studies indicate that rates of CUD in recreational cannabis users 
range from 11-15% (Compton, Han, Jones, Blanco, & Hughes, 2016) to approximately 
30% (Hasin et al., 2015). Interestingly, a more recent study found that increased access to 
medical cannabis (MC) programs (at the time of the study 28 states and Washington DC 
had legalized MC) was associated with higher rates of adult cannabis use, but was not 
associated with higher rates of CUD (Williams, Santaella-Tenorio, Mauro, Levin, & 
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Martins, 2017), raising the question of whether MC use could be associated with a lower 
risk for CUD than recreational cannabis use. 
As a full diagnostic assessment is quite time-consuming and therefore often not 
feasible in many clinical settings, several tools have been developed to screen for CUD in 
both clinical and research settings, including the Severity of Dependence Scale (SDS) 
(Gossop et al., 1995); Cannabis Abuse Screening Test (CAST) (Legleye, Kraus, Piontek, 
Phan, & Jouanne, 2012); Alcohol, Smoking and Substance Involvement Screening Test 
(ASSIST) (WHO Assist Working Group, 2002); Cannabis Use Problems Identification 
Test (CUPIT) (Bashford, Flett, & Copeland, 2010); Cannabis Use Disorders 
Identification Test (CUDIT) (Adamson & Sellman, 2003) and its revised version 
(CUDIT-R) (Adamson et al., 2010). While each has strengths, the CUDIT-R was selected 
for inclusion in the current study as it is commonly used for clinical and research 
applications, is based on DSM criteria, and offers sound psychometric properties when 
used to assess recreational cannabis users (Adamson et al., 2010).  
To date, no studies thus far have directly addressed whether MC patients develop 
symptoms/behaviors associated with problematic cannabis use. Given the growing 
number of MC patients, it is important to accurately assess potential problematic 
cannabis use in this population. Accordingly, data was collected from patients interested 
in using MC prior to their initiation of use, and all patients were re-queried following 3, 6 




Using the CUDIT-R, symptoms and behaviors related to problematic cannabis use 
were examined over the course of treatment with the hypothesis that MC patients would 
exhibit increased frequency of use, but endorse few problems associated with MC use 
given their primary motivation for use is symptom alleviation. Further, it was predicted 
that increased exposure to non-intoxicating constituents like cannabidiol (CBD) would 
not be associated with higher CUDIT-R scores in MC patients, whereas increased 
exposure to delta-9-tetrahydrocannabinol (THC), the primary intoxicating constituent of 
cannabis, may be related to higher CUDIT-R scores. It was also hypothesized that MC 
patients would exhibit lower CUDIT-R scores relative to a cohort of recreational (i.e., 
non-medical) cannabis users, whose primary motivation for cannabis use is to feel 
intoxicated or “high.” Importantly, a recent study assessing the internal consistency and 
structural validity of the CUDIT-R in veteran MC patients reported that although the 
CUDIT-R demonstrated acceptable, yet modest, internal consistency in this cohort, the 
traditional single-factor structure of the scale “showed poor fit” (Loflin, Babson, Browne, 
& Bonn-Miller, 2018). As results raise the possibility that CUDIT-R scores may not 
accurately reflect problematic use in certain populations of MC patients, analyses were 
also conducted to determine whether the CUDIT-R has acceptable internal consistency 
and reliability in the current sample of MC patients.  
Methods 
Prior to participation, all participants completed an informed consent process in 
which study procedures were thoroughly explained. Participants interested and willing to 
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participate read and signed an informed consent form, which describes the procedures, 
risks, benefits, and voluntary nature of the study. This study was approved by the 
Partners Healthcare Institutional Review Board. 
Participants & Study Design 
As part of an ongoing, longitudinal study of MC patients conducted at McLean 
Hospital (PI: Dr. Staci Gruber; funded private donors, foundations, and unrestricted gifts 
to the Marijuana Investigations for Neuroscientific Discovery [MIND] program at 
McLean Hospital), individuals interested in using MC, but who had not yet begun 
treatment were recruited. All study participants were enrolled between September 2014–
November 2019 and completed assessments at McLean Hospital. Individuals were 
considered eligible for the current study if they were aged 21 or older, had an estimated 
IQ of at least 75 assessed using the Wechsler Abbreviated Scale of Intelligence (WASI) 
(Wechsler, 1999), and planned to use cannabinoid-based products to treat 
medical/psychiatric conditions. All patients were required to have a certification for MC 
or plan to use products not requiring certification (i.e., hemp-derived products). At 
baseline, participants were required to be cannabis naïve or, if they reported a history of 
previous recreational cannabis use, were required to be abstinent from regular use for one 
year or more in order to minimize the effects of previous cannabis exposure. All patients 
were required to test negative for urinary THC and could not have begun MC treatment. 
 Patients completed baseline assessments, including medical history 
questionnaires, cognitive testing, and self-report rating scales (reported in Chapter 3), as 
well as multimodal neuroimaging prior to initiation of regular MC treatment; however, 
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only data from the CUDIT-R self-report scale are reported in this chapter. MC patients 
returned for follow-up visits after three, six, and twelve months of MC use. At follow-up 
visits, patients’ MC regimen information was captured using detailed MC diary 
information and a timeline followback procedure (TLFB) (Robinson, Sobell, Sobell, & 
Leo, 2014b; Sobell et al., 1988), which was modified and optimized to collect recent 
cannabis use data through the additional of targeted queries regarding specifics of MC 
treatment (product used, mode of use, amount purchased, amount used, etc.). At the time 
of analyses, 54 patients completed a baseline visit and had returned for at least one 
follow-up visit. Of the 54 MC patients included in the current analyses, 28 completed all 
four visits. Six patients missed an interim visit (1 of the 6 patients missed 2 interim 
visits), but all completed baseline and 12-month follow-ups. Ten MC patients are “in 
progress” as they are currently enrolled but are awaiting their next follow-up timepoint. 
Ten individuals were discontinued from the study as they either stopped MC use (n=3) or 
were lost to follow-up (n=7). Of those who were lost to follow-up, three reported that 
they discontinued for reasons unrelated to MC treatment; however, four individuals 
stopped responding to contact by study staff and information about the reason for 
discontinuation could not be gathered. A schematic summarizing this info is presented in 
Chapter 3 (Figure 3.1). See Statistical Analyses for information about how missing MC 
patient data were handled.  
In addition, as a comparison, previously acquired CUDIT-R data from 38 heavy 
recreational cannabis users was included from participants enrolled in a previous study 
(Marijuana: Neurobiologic Correlates of Age of Onset, R01 DA03264601); all 
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participants in this cohort reported more than 1500 lifetime cannabis uses and reported 
current cannabis use four or more days per week, as assessed using the modified TLFB. 
Recreational cannabis users were also required to be free of Axis I pathology including 
current or previous drug/alcohol use disorders (other than cannabis) as assessed by the 
Structured Clinical Interview for DSM-IV – Patient Edition (SCID-P) (First, Spitzer, 
Gibbon, & Williams, 1994).  
CUDIT-R 
The CUDIT-R is an 8-item self-report screening tool designed to detect 
problematic cannabis use. Symptoms assessed include frequency of use; hours stoned 
during days of cannabis use; inability to stop using once started; failure to meet 
expectations; time spent getting cannabis, using cannabis, or recovering from cannabis; 
memory or concentration problems after cannabis use; using in hazardous situations (e.g., 
driving, operating machinery, caring for children); and desire to stop/reduce cannabis use. 
Seven of the eight items are scored on a scale ranging from 0-4 (higher 
frequency/severity of symptoms are reflected by higher ratings), while the final question 
regarding thoughts about cutting down use is scored as 0 (no), 2 (yes, but not in the past 6 
months), and 4 (yes, during the past 6 months). Scores are summed to generate a total 
score, ranging from 0 to 32. A total score of 8 or more reflects “hazardous cannabis use,” 
while scores of 13 or more indicate “possible CUD”; diagnostic measures, such as the 
SCID, are needed for definitive CUD diagnosis.  
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Cannabinoid Exposure in MC Patients 
As an observational study, all patients chose their own MC treatment regimens, 
which were closely tracked using a number of metrics. All MC patients were asked to 
record MC treatment regimen information in paper-and-pencil or electronic drug diaries 
(based on patient preference) once a regular MC use regimen was established. Further, 
study participants were contacted by phone to complete monthly check-in visits to 
corroborate drug diary information using the modified TLFB. Through these methods, 
patients were asked to provide qualitative information regarding product type and mode 
of use (i.e., joint, vaporizer, solution/tincture, edibles, capsules, topicals, etc.) and 
quantitative information regarding frequency (episodes of MC use/week) and amount of 
product used. These data were then reviewed and clarified at in-person visits and allowed 
for the calculation of average number of MC uses per week. MC patients were also asked 
to provide constituent information based on product labels and/or certificates of analyses 
from dispensaries or product websites. Additionally, patients sent samples of their most 
frequently used MC products to an outside laboratory for analyses (ProVerde 
Laboratories, Inc.), including cannabinoid constituent profiling. These analyses provide 
information about THC and CBD levels as well as a number of other cannabinoids. For 
all patients with available product data, standard metrics of cannabinoid exposure (mg of 
THC and CBD used per week) were calculated for each interval between study visits 




Over the course of MC treatment, MC patients’ CUDIT-R scores (total scores and 
individual item scores) were examined using repeated measures analyses of covariance 
(rmANCOVAs), controlling for age, sex, and education. In cases where significance was 
noted, follow-up rmANCOVAs were conducted to compare baseline data to each follow-
up visit (e.g., baseline vs. 3 months, baseline vs. 6 months, baseline vs. 12 months). 
As not all patients included in the current analyses completed all four study visits, 
those with missing data were divided into two discrete groups: 1) data missing at random 
(MAR; n=47) and 2) unknown whether data were MAR (n=7). Data were considered 
MAR for MC patients who completed the study but had missed a visit(s), enrolled 
individuals who are still considered “in progress,” and those who reported withdrawing 
from the study due reasons unrelated to MC use. For those who stopped MC treatment or 
were lost to follow-up for unknown reasons, analyses were conducted to determine 
whether missing data could be considered MAR. Specifically, changes in self-report 
ratings related to MC treatment outcomes between baseline and 3 months were compared 
between 1) those who remained enrolled throughout the 12-month timepoint, are “in 
progress,” or withdrew from the study for reasons unrelated to MC use and 2) those who 
stopped using MC or were lost to follow-up for unknown reasons. As no significant 
between-group differences emerged for any of these variables, it was determined that 
data were MAR. Accordingly, imputation for missing data was conducted using last 
observation carried forward (LOCF) for those who were in progress, stopped using MC, 
or lost to follow-up. For those who missed only interim visits, missing CUDIT-R data 
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were imputed by taking an average of scores from the visits preceding and following the 
missed timepoint(s) for each variable. 
To examine the impact of MC use variables on abuse liability, partial correlations 
(2-tailed) controlling for age, sex, and education were utilized to explore the relationship 
between total CUDIT-R scores and frequency of MC use (episodes of use/week), THC 
exposure (mg/week), and CBD exposure (mg/week). Given that the 3-month study visit 
contained the fewest imputed data points, CUDIT-R scores from this visit were utilized 
for these analyses. 
Two-group comparisons were conducted in order to compare MC patients to 
recreational cannabis users. Chi-squared analyses were used to compare sex and race 
frequencies between groups, and for continuous variables (age, education, IQ, cannabis 
use episodes, and CUDIT-R scores), one-way ANOVAs were conducted. One-way 
ANCOVAs controlling for age, education, and sex were also conducted to compare 
CUDIT scores between groups, and results are reported with effect sizes (partial eta 
squared) and 95% confidence intervals based on estimated marginal means. Again, given 
that the 3-month timepoint had the greatest sample size (n=51) and therefore contained 
the least amount of imputed data, CUDIT-R scores from MC patients’ 3-month follow-up 
visits were compared to scores in the recreational cannabis users. Although Levene’s test 
of homogeneity was violated when comparing the two groups, non-parametric tests did 




Finally, to assess the internal consistency and reliability of the CUDIT-R in MC 
patients and recreational cannabis users, corrected item-scale correlations were performed 
for the MC patient group as well as the recreational cannabis-using group. Total 
Cronbach’s alpha was calculated for the entire scale and item-deletion analyses were 
completed to assess the internal consistency of each CUDIT-R item. Data from MC 
patients’ follow-up visit after 3 months of use were also utilized for Cronbach’s analyses. 
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Note: Cronbach’s Alpha analyses were also conducted to assess the validity of the CUDIT-R in the MC 
patients as well as the recreational cannabis users. 
Table 4.1. Chapter 4: Statistical Analyses Overview 
Results 
MC Patients: Demographics 
MC patients (20M, 34F) were between the ages of 22-78, primarily White 
(88.89%), reported approximately 16 years of education, and exhibited above average IQ. 
See Table 4.2 for demographics. Patients reported using MC to treat symptoms of pain 
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(n=33), anxiety (n=31), sleep (n=22), mood (n=14) attention (n=4), and other general 
medical conditions (e.g., gastrointestinal disorders; n=4); 36 patients reported using MC 
for more than one indication. As noted in Table 4.3, MC patients reported abstinence 
from regular recreational cannabis use from 3-47 years upon enrolling in the current 
study, and none had initiated a MC treatment regimen, as this was a requirement for the 
study. Over the course of the study, patients reported using MC 9-11 times/week on 
average, and THC exposure was notably lower than CBD exposure at each visit.  
 
DEMOGRAPHICS (n=54) Mean (SD) Median [Range] 
Sex 20 Male (37.04%) 
34 Female (62.96%) -- 
Race 48 White (88.89%) 
5 Non-White (9.26%) 
1 Prefer Not to Answer (1.85%) 
-- 
Age 49.17 (16.45) 52.5 [22-78]  
Education 16.58 (2.08) 16 [12-21] 
WASI IQ 121.02 (7.54) 120.5 [99-134] 
WASI=Wechsler Abbreviated Scale of Intelligence; NSAIDs = Nonsteroidal anti-inflammatory 
drugs 
a n=12, b n=20, c n=7, d n=18, e n=29, f  n=14, g n=11 





CANNABIS USE Mean (SD) Median [Range] 
Duration of cannabis abstinence (years)b† 23.57 (14.20) 25 [3-47] 
MC Uses/Week   
Baseline to 3 Monthsa 9.49 (6.26) 9 [1.14-30.02] 
3 Months to 6 Monthsb 10.17 (8.10) 7.2 [0.66-38.50] 
6 Months to 12 Monthsc 11.48 (8.14) 8.8 [0.75-30.63] 
THC mg/week   
Baseline to 3 Monthsd 63.64 (184.22) 10.22 [0-1000.50] 
3 Months to 6 Monthse 41.78 (78.83) 11.62 [0-321.55] 
6 Months to 12 Monthsf 38.43 (51.76) 18.56 [0-210.92] 
CBD mg/week   
Baseline to 3 Monthsd 154.97 (287.28) 29.43 [0-1303.99] 
3 Months to 6 Monthse 205.39 (320.84) 83.33 [0-1434.26] 
6 Months to 12 Monthsf 101.91 (262.46) 47.61 [0.24-1228.12] 
MC = medical cannabis; THC=delta-9-tetrahydrocannabinol; CBD=cannabidiol  
a n=52, b n=46, c n=28, d  n=38, e n=32, f n=21 
†Average abstinence is reported for n=28 with a previous history of regular cannabis use; n=26 
reported no previous regular cannabis use or were cannabis naïve  
Table 4.3. MC Patient Medical Cannabis/Cannabinoid Use. 
 
MC Patients: CUDIT-R 
rmANCOVAs demonstrated that total CUDIT-R scores increased in MC patients 
over the course of the study. Analyses comparing each follow-up visit to baseline 
revealed that increases were significant after 3 and 6 months of use, but not at 12 months 
(see Table 4.4; Figure 4.1). Although ratings increased, average total CUDIT-R scores 
for MC patients fell below the threshold for ‘hazardous use’ (score of 8 or more) at each 
visit and well below the cutoff for possible CUD (score of 13 or more); average total 
CUDIT-R scores were ≤6.10 across all follow-up visits. Of the 54 patients included in the 
study, the number of MC patients who surpassed the threshold for possible CUD at each 
visit is as follows: Visit 1 = 0, Visit 2 = 2, Visit 3 = 2, Visit 4 = 3. 
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In order to determine which specific symptoms/behaviors contributed to total 
CUDIT-R score increases, changes in individual item scores were also examined (Table 
4.4; Figure 4.2). “Frequency of use” and “failure to meet expectations” were the only 
two variables for which significant changes were observed over time. Follow-up analyses 
revealed that frequency of use was significantly higher at each visit relative to baseline, 
whereas failure to meet expectations was only significant at 3 months relative to baseline. 
However, an examination effect sizes and power indicated that while observed power for 
changes in frequency of use ranged from 80-95%, statistical power was low for failure to 
meet expectations (54%). Moreover, significant increases in scores for “failure to meet 
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Significant values (p≤.05) are bolded. Degrees of freedom (df)=1,50 




Figure 4.1. Total CUDIT Scores over 12 months of MC Treatment.  
 
 




Correlation Analyses: CUDIT-R and MC Use Variables 
Partial correlations assessing the relationship between total CUDIT-R scores and 
MC use variables revealed no significant relationships between number of MC episodes 
per week (r(44)=.11, p=.46), THC mg/week (r(32)=.27, p=.12) or CBD mg/week 
(r(32)=.07, p=.72). 
MC Patients vs Recreational Cannabis Users 
MC patients and recreational users were also directly compared in order to 
examine potential differences in CUD symptoms among these groups. Demographic and 
cannabis use information for MC patients and recreational users is reported in Table 4.5.  
In terms of cannabis use, TLFB data indicated that recreational users significantly 
reported more episodes of cannabis use per week relative to MC patients, although on 
average both cohorts reported more than daily use. Analyses examining differences in 
CUDIT-R scores between MC patients and recreational cannabis users revealed 





Variable Mean (SD) Chi-Square 






Sexa (20M, 34F) (30M, 9 F) 14.49 <.01 
Racea 
48 White (88.8%) 
5 Non-White (9.26%) 
1 Prefer Not to Answer (1.85%) 
26 White (66.67%) 
12 Non-White (30.77%) 
1 Prefer Not to Answer (2.56%) 
10.14 .04 
   ANOVA 
   F p  (η2) 
Ageb 49.17 (16.45) 23.18 (5.84) 88.95 <.01 (.49) 
Educationb 16.56 (1.99) 14.18 (1.99) 32.40 <.01 (.26) 
WASI IQc 121.02 (7.54) 118.92 (9.49) 6.77 .01 (.07) 
Cannabis 
uses/weekd 9.26 (6.33) 15.89 (11.51) 11.81 
.01 
(12) 
Significant values (p≤.05) are bolded.  
WASI= Wechsler Abbreviated Scale of Intelligence 
aDegrees of freedom (df)=1; bdf=1,91; cdf=1,90; ddf=1,86 
Table 4.5. Demographics: MC Patients vs. Recreational Cannabis Users. 
 







 Mean (SD) Mean (SD) F p (η2) 
Total Score 5.99 (2.71) 15.36 (5.31) 50.05 <.01 (.36) 
Frequency 3.45 (0.81) 3.92 (0.27) 7.71 <.01 (.08) 
Hours Stoned 0.69 (0.97) 2.13 (0.95) 12.34 <.01 (.12) 
Can’t Stop 0.12 (0.48) 1.15 (1.51) 22.22 <.01 (.11) 
Failure to Meet 
Expectationsb 0.21 (0.60) 0.67 (1.06) 6.45 .01 (.07) 
Time Spent Getting 
Cannabis/Recovering 0.15 (0.36) 1.59 (1.48) 13.35 <.01 (.13) 
Memory/Attention 
Problems 0.45 (0.90) 1.54 (1.31) 9.68 <.01 (.10) 
Use in Hazardous 
Situations 0.20 (0.63) 1.54 (1.60) 12.58 <.01 (.13) 
Thought about Cutting 
Down Use 0.71(1.45) 2.82 (1.35) 26.60 <.01 (.23) 
Significant values (p≤.05) are bolded. 
a Degrees of freedom (df)=1,88 
Table 4.6. CUDIT Scores: MC Patients vs. All Recreational Consumers.  
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CUDIT-R Internal Consistency and Reliability 
Although the CUDIT-R has been validated in recreational cannabis users, it 
remains questionable whether this tool is appropriate for use in MC patients. Given that 
MC patients demonstrated increases in total overall scores on the CUDIT-R in the 
absence of significant increases in problematic symptoms, analyses were conducted to 
examine internal consistency and reliability of the CUDIT-R in MC patients as well as in 
recreational cannabis users.  In the current sample of MC patients, the CUDIT-R had an 
unacceptable level of internal consistency (alpha=.27). As noted in Table 4.7, 
unacceptable levels are indicative of α < 0.5, whereas acceptable levels begin at α ≤ 0.7. 
Cronbach's alpha Internal consistency 
0.9 ≤ α Excellent 
0.8 ≤ α < 0.9 Good 
0.7 ≤ α < 0.8 Acceptable 
0.6 ≤ α < 0.7 Questionable 
0.5 ≤ α < 0.6 Poor 
α < 0.5 Unacceptable 
Table 4.7 Cronbach’s Alpha Descriptors 
 Moreover, removing frequency of use from the analyses increased internal 
consistency and reliability (alpha=.39), as did removal of thoughts about cutting down 
use (alpha=.45). Given that alpha increased after removing these items, it appears that 
frequency of use and thoughts of cutting down cannabis use are not assessing the same 
construct as the remainder of CUDIT-R items in a cohort of MC patients. In addition, 
following removal of these items, alpha remained below the level of acceptable internal 
consistency, suggesting that the CUDIT-R is likely not an appropriate measure for 
assessing CUD among MC patients. Conversely, when Cronbach’s alpha was calculated 
for recreational users’ CUDIT-R scores, internal consistency was much improved, but by 
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some conventional standards is considered questionable (alpha=.63). As alpha did not 
improve with the removal of any individual CUDIT-R items, results suggest that all items 
assess a similar construct (CUD) in recreational users. 
Discussion 
Findings from the CUDIT-R suggest that, on average, MC patients in this study 
do not meet the threshold for ‘hazardous’ cannabis use over the course of 12 months of 
MC treatment. When examining total CUDIT-R scores in each individual MC patient, a 
small number of individuals did surpass the threshold for possible CUD following 
initiation of MC treatment (2 patients after 3 months and 6 months, and 3 patients after 
12 months). However, findings revealed that CUDIT-R ratings, including total scores and 
all individual item scores were significantly lower in MC patients relative to heavy 
recreational cannabis users. Moreover, Cronbach’s alpha analyses revealed that the 
CUDIT-R does not have acceptable levels of internal consistency within MC patients. 
Overall, despite significantly increased frequency of use, individual item analysis 
also revealed other signs of problematic use were generally not endorsed. It is of note that 
while failure to meet expectations demonstrated a statistically significant increase after 3 
months of treatment, this was the only visit for which an increase was considered 
significant and observed statistical power for this finding was low (1-β=.54). 
Despite the fact that the frequency of use CUDIT-R item score significantly 
increased at follow-up visits relative to baseline in MC patients, correlation analyses 
more closely examining the relationship between MC use variables and CUDIT-R scores 
found that frequency of use, in terms of specific number of MC episodes per week, is not 
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significantly correlated with increased total CUDIT-R scores in MC patients. Therefore, 
frequency of MC use does not appear to be a useful indicator of problematic use in MC 
patients, especially as patients taking a medicine generally do so on a daily basis; the 
same is to be expected with MC. Although it was expected that individual cannabinoid 
exposure would be related to MC use, correlation analyses did not reveal significant 
relationships between THC or CBD exposure and total CUDIT-R scores.   
As noted above, comparisons between MC patients and recreational cannabis 
consumers suggest that those with heavy recreational use demonstrate significantly 
higher levels of problematic cannabis use, while most MC patients do not appear to 
exhibit symptoms consistent with a diagnosis of CUD. Notably, recreational consumers 
did report using cannabis about 1.7 times as often as MC patients. It is therefore possible 
that higher frequency of use beyond a certain threshold could be a factor that may predict 
the manifestation of some of the symptoms of CUD. However, as previously mentioned, 
no relationship was observed between MC episodes of use per week and CUD symptoms 
in this sample of MC patients who use cannabis quite frequently (more than daily on 
average) and exhibit few signs of problematic use. It is therefore likely that factors other 
than frequency of use contribute to the development of CUD symptoms and behaviors. 
To date, additional contributing factors have yet to be empirically examined, but 
motivation for use, product choice, and age of onset of cannabis use are important 
variables to consider. 
Although the CUDIT-R is considered a well-validated screening tool for CUD, it 
was developed for use with recreational cannabis users, and not for MC patients. The 
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current analyses suggest that the CUDIT-R does not appear to be valid as a screening tool 
among those who use cannabis for medical purposes given both the extremely low 
Cronbach’s alpha, as well as qualitative analysis of the CUDIT-R items and review of 
their applicability to MC patients. Accordingly, although some patients did surpass the 
threshold for potential CUD at follow-up visits, these numbers are likely not a valid 
representation of the number of MC patients who actually develop a use disorder.  
To date, one other study has assessed the validity of the CUDIT-R in a 
subpopulation of veteran MC populations (Loflin et al., 2018). Although the authors 
reported that the CUDIT-R’s internal consistency fell within the acceptable range, 
Cronbach’s alpha calculated in that study is considered modest (alpha=.73), and 
confirmatory factor analysis revealed that the single-factor model used by the CUDIT-R 
to indicate potential CUD only accounted for 38.34% of variance in their sample. 
Similarly, in the current study, within the MC group removal of “frequency of use” and 
“thoughts about cutting down use” increased the overall alpha of the CUDIT-R, which 
suggests that these items may be assessing a different construct than the other items of 
this scale. For example, taking a medication regularly can be a sign of treatment 
adherence rather than a sign of problematic use. Instead, it may be more helpful to 
differentiate regular use from using more than needed to achieve a therapeutic benefit, as 
the former could potentially be more indicative of problematic use. In addition, thoughts 
about cutting down use could indicate that patients may feel as though they do not need 
as much MC to get the same effect, or endorsement of this item may be a function of 
individuals feeling the financial burden related to the cost of MC treatment, especially as 
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it is not covered by insurance. In addition, other questions on the CUDIT-R may not be 
directly reflective of problematic use in MC patients either. Specifically, “time spent 
getting cannabis” may not be problematic, but simply reflect the geographic distance 
some patients travel, or the time patients wait to purchase MC products for symptom 
relief that, in some cases, is not achieved with conventional medications.  
Taken together, current views of CUD may need to be amended in order to 
capture signs of problematic use among MC patients (Sznitman & Room, 2018). As in 
the case of opioid use disorder, for example, tolerance and withdrawal criteria are not 
considered to be met for individuals who are using opioids under appropriate medical 
supervision. With regard to cannabis, similar exclusions from these DSM-5 criteria may 
need to be applied. It also is likely that signs of problematic use manifest differently in 
MC patients who have a markedly different motivation for cannabis use – symptom 
alleviation – relative to recreational users who use cannabis specifically to alter their state 
of being or to feel “high.” As a result, MC patients and recreational users tend to seek 
different cannabis products and therefore often have different levels of exposure to 
specific cannabinoids. Typically, recreational users seek products with high levels of 
THC, which is generally associated with negative neurobiologic outcomes, to achieve 
mood-altering effects. Further, chronic exposure to THC is thought to alter excitatory and 
inhibitory signaling in certain brain regions that could ultimately affect reward processing 
(Parsons & Hurd, 2015). Altered reward processing is closely linked to addictive 
disorders given that intoxication produces pleasurable feelings, which leads to repeated 
use as an individual seeks achieve these rewarding effects (Everitt & Robbins, 2016). In 
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addition, it is important to note that using products with higher levels of THC has also 
been associated with increased addiction severity (Freeman & Winstock, 2015b).  
MC patients may use products containing THC, but many seek products with 
varied cannabinoid constituent profiles that are often less intoxicating or even non-
intoxicating. Specifically, many MC patients choose products with high levels of CBD, 
known for its therapeutic benefits and potential neuroprotective properties (Blessing, 
Steenkamp, Manzanares, & Marmar, 2015; de Mello Schier et al., 2014; Fernandez-Ruiz 
et al., 2013; Iseger & Bossong, 2015; Zuardi, 2008). Calculations of overall THC and 
CBD exposure suggest that this preference is reflected in the current study sample, as MC 
patients as a group had substantially higher CBD exposure at each study visit relative to 
THC exposure. CBD has also been shown to limit or mitigate negative effects associated 
with THC (Englund et al., 2013; Morgan & Curran, 2008; Morgan et al., 2012; Morgan, 
Schafer, Freeman, & Curran, 2010; Yucel et al., 2016; Zuardi et al., 1982), and 
preliminary data from both animal and human studies suggest that CBD may have 
efficacy in the treatment of substance use disorders, including nicotine (Morgan, Das, 
Joye, Curran, & Kamboj, 2013), cocaine (Lujan, Castro-Zavala, Alegre-Zurano, & 
Valverde, 2018), and opioids (Hurd et al., 2019; Hurd et al., 2015). Further, one case 
study suggests positive effects of CBD in treating CUD (Shannon & Opila-Lehman, 
2015). Although relationships between individual cannabinoid exposure and CUDIT-R 
levels were not detected in the current study, future studies are encouraged to continue to 
examine this as a possibility, particularly once valid screening measures of CUD are 
developed for MC patients. 
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It is also of note that our analyses of a previously recruited cohort of recreational 
CAN users revealed “questionable” levels internal consistency. However, a number of 
factors impacting the interpretation of Cronbach’s alpha must be considered and may 
account for this only modest alpha level (Field, 2013). First, Cronbach’s alpha is often 
more robust when scales contain a large number of items; as the CUDIT only has eight 
items, this may have diminished internal consistency. Further, for this study, a well-
characterized group of heavy, cannabis users with specific cannabis use criteria, limited 
other drug use, and no other psychopathology was recruited, which inherently restricts 
the range and variability among the sample. In validation studies, a wider range of 
individuals is typically recruited to represent a more varied population. Accordingly, the 
modest level of alpha is recreational users may be a function of these factors, rather than 
an indication that this scale is not appropriate for CUD screening in recreational cannabis 
users. 
Limitations & Future Directions 
Data from the current study indicate that most MC patients do not reach the 
threshold of symptom severity using a common screening tool for CUD. These findings 
must be considered in light of several limitations. First, a definitive diagnosis of CUD can 
only be made using a diagnostic interview like the SCID. In the current study, MC 
patients receive the SCID at baseline (prior to initiation of MC use) in order to rule out 
exclusionary psychopathologies. The CUDIT-R was selected for use in this study as it is 
widely used screening tool in both research and clinical settings and sometimes serves as 
a proxy for diagnostic instruments generating data regarding CUD. Further, items on the 
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CUDIT-R have high overlap with DSM-5 criteria for CUD. However,  it is important to 
note that this instrument was developed before the release of the DSM-5, and therefore 
based on DSM-IV criteria. Although most criteria are similar between these two versions 
of the DSM, “craving or desire to use cannabis” is a new addition to the DSM-5 criteria 
and is not reflected in the CUDIT-R. Interestingly, however, when the original CUDIT 
was revised, an item assessing legal problems related to cannabis use was removed; this 
criterion was also eliminated in the transition from DSM-IV to DSM-5. All other 
CUDIT-R items reflect current DSM-5 CUD criteria which is, at least in part, why it 
remains a popular screening tool for CUD assessment.  
Currently, sample sizes are moderate for follow-up visits following 3- and 6-
months visits, but fewer participants have completed a 12-month follow-up. In addition, 
due to the fact that a number of participants are still “in progress,” and a small group was 
also lost to follow-up, missing data was imputed after it was determined these data appear 
to be missing at random. Commonly used mean imputation and LOCF methods were 
implemented; however, drawbacks must be acknowledged when using these approaches. 
Although mean imputation and LOCF are both straightforward and easily implemented, 
they greatly reduce the variance of the dataset. Further, LOCF assumes that the data will 
not change over time and has the potential to produce values that may not actually be 
reflective of the true data  (Shoop, 2015). Future analyses will benefit from more 
advanced imputation strategies, including multiple or Bayesian imputation which can 
help address some of the limitations of the current approach. 
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Plans for the ongoing, longitudinal study involve monitoring CUDIT-R scores in 
larger samples and over longer durations of time (up to two years). However, longitudinal 
studies assessing patients over the course of several years may be necessary to detect 
potential development of problematic cannabis use. In addition, MC patients who were 
cannabis naïve or who had limited recent cannabis exposure were specifically recruited, 
and all patients reported a primary goal of symptom alleviation. Given that many MC 
patients in the current sample appear to be “pure” medical users, they may represent a 
unique group of patients. As such, results may not be generalizable to other populations 
of cannabis consumers such as “mixed” users who use cannabis both medically and 
recreationally. 
Similarly, findings may not apply to MC patient populations who tend to choose 
products with higher amounts of THC than CBD, as patients in the current sample overall 
reported notably higher exposure to CBD. Despite potential limited generalizability, this 
study represents the first face-to-face, direct assessment of CUD in MC patients pre- vs 
post-MC treatment. Although findings may appear to be in contrast with the limited 
existing literature suggesting that rates of CUD are comparable between MC patients and 
recreational cannabis users (Lin, Ilgen, Jannausch, & Bohnert, 2016). However, using Lin 
and colleagues’ recent study as an example, the authors did not differentiate those who 
exclusively use cannabis for medical reasons from those who also use recreationally. 
Further, their data is based on the National Survey on Drug Use and Health (NSDUH), 
which employs questions that are very similar to those asked in the CUDIT-R, which is 
problematic as results from the current study demonstrate that these types of queries are 
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not valid for assessing CUD in MC patients. Problematic cannabis use is likely a unique 
construct among those using cannabis medically, and novel tools are therefore needed for 
this unique population of cannabis consumers.  
An additional limitation is related to the fact that MC patients and recreational 
cannabis users were recruited for separate studies and are not matched on demographic 
variables. Although age, sex, and education were controlled for in comparisons between 
MC patients and recreational cannabis users, these populations had additional 
demographic differences that may have influenced study findings. Future studies 
comparing MC patients to recreational users should recruit both groups in parallel and 
ensure individuals are well-matched. 
Conclusions 
In the current study, MC patients generally exhibit low risk patterns of cannabis 
use, as average scores indicate they MC patients generally do not meet CUDIT-R criteria 
for hazardous use or possible CUD. Although some patients did surpass the threshold for 
CUD after initiation of MC use, these data likely do not reflect rates of CUD in MC 
patients given that analyses also suggest that the CUDIT-R is not a valid measure for 
assessing CUD in those who use cannabis for medical purposes. Taken together, 
development of new metrics is needed to assess CUD in MC patients, and future studies 
should examine these new tools in larger and more diverse samples, including those who 
may use cannabis for both medical and recreational purposes.  
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CHAPTER FIVE  
Discussion 
Recreational vs. Medical Cannabis Use: Explaining Cognitive Outcomes and Cannabis 
Use Disorder Findings 
The three studies included in previous chapters explore the impact of cannabis use 
on cognition in recreational users and medical cannabis (MC) patients, as well as the 
potential for development of problematic cannabis use. Throughout these chapters it 
becomes clear that a number of factors can influence findings when assessing both 
recreational cannabis users and MC patients. Although null findings were observed for 
several hypotheses, most notably alterations in cognitive functioning were not observed 
in either recreational consumers (for which decrements were predicted) and MC patients 
(for which improvements were hypothesized), it is important to recognize methodological 
limitations of the current studies may have impacted results rather than conclude that 
cannabis use does not impact cognition. Further, in the MC patients, it is also important 
to acknowledge that while previous research has indicated decrements in recreational 
users, MC patients in the current study did not exhibit any significant declines in 
cognitive functioning. Stable performance is also notable given that many MC patients 
included in the current study were older adults, who may be vulnerable to age-related 
cognitive decline. Accordingly, the goal of the following discussion is to consider aspects 
of cannabis use that require further exploration and consideration based on both previous 
research as well as findings from previous chapters that were significant, albeit 
preliminary in some cases.  
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In the majority of research studies, recreational users, like those included in the 
previous chapters, are typically comprised of young individuals (adolescents, emerging 
adults, and young adults) who are using or began using cannabis regularly and heavily 
during critical neurodevelopmental phases of life. In fact, all cannabis users included in 
Chapter 2, regardless of whether they were classified as early or late onset, initiated 
regular use of cannabis during adolescence or emerging adulthood (between ages 11-23). 
As this study was underpowered, it is likely that subtle decrements in these recreational 
cannabis users exist but could not be detected with the current analytic approach. 
Comparing those who initiate recreational use during adolescence/emerging adulthood to 
those who begin using regularly in later adulthood will be important to address in future 
investigations.  
As recreational users’ main goal of cannabis use is to feel high or altered, 
products with high levels of THC are typically chosen by this cohort. In fact, studies have 
shown that THC potency continues to rise dramatically in recreational cannabis products, 
while CBD levels have fallen to virtually undetectable levels (Chandra et al., 2019; 
ElSohly et al., 2016). This trend is problematic given that higher doses of THC are 
associated with increased cognitive impairment (Kowal et al., 2015; Morgan et al., 2012; 
Ramaekers et al., 2006), whereas CBD may be able to prevent or limit these negative 
effects. This combination of being young and being exposed to high levels of THC while 
neurodevelopmentally vulnerable is likely problematic. Although this pattern was not 
observed in the current study of recreational users, many patients were recruited several 
years ago prior to such drastic increases in THC potency. Further, in general, recreational 
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users included in the current sample were highly educated and intelligent, which may 
serve as a protective factor against negative consequences associated with THC exposure. 
Although some studies have attempted to examine higher potency products, most 
observational studies to date have simply asked participants about their products’ potency 
(Large & Nielssen, 2017; Rigucci et al., 2016). In fact, it appears that no studies thus far, 
other than acute challenge paradigms, have directly assessed the impact of the use of high 
potency products; this is a major gap in the literature that warrants additional research. 
In contrast, MC patients are typically middle-aged to older adults who often times 
use products that are less intoxicating or even non-intoxicating. First, as adults, most of 
whom are well beyond the window of critical neurodevelopment, cannabis is likely to 
have a differential impact on the aging endocannabinoid system (ECS) and, subsequently, 
cognitive outcomes. Based on preclinical evidence, some postulate that due to age-related 
changes in the ECS, exogenous cannabinoids may actually exert positive effects on 
cognition in older individuals (Weinstein & Sznitman, 2020), many of whom have 
actually begun to experience age-related cognitive decline. In addition, MC patients, who 
are searching for symptom alleviation, often choose products with more varied 
cannabinoid profiles than recreational users. In the current study, for example, MC 
patients reported higher exposure to CBD relative to THC. In general, CBD is touted as 
being neuroprotective, and although THC is commonly associated with negative effects, 
emerging preclinical evidence suggests that THC may also have its own neuroprotective 
effects in older populations. Specifically, THC has been shown to improve cholinergic 
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transmission and inhibit the aggregation of amyloid-beta (Weinstein & Sznitman, 2020), 
a protein implicated in the development of Alzheimer’s disease. 
Differences in cognitive performance, although not observed in the current study, 
are widely documented in the literature and often involve decrements in 
executive/inhibitory function in recreational users (Crean et al., 2011; Sagar & Gruber, 
2019). This executive dysfunction may, in turn, affect risk for cannabis use disorder 
(CUD). In young, recreational consumers, it is possible that the even mild executive 
function decrements, combined with high, premorbid levels of impulsivity could 
influence the potential for the development of CUD. As seen in Chapter 2, recreational 
cannabis users reported significantly higher levels of self-reported impulsivity relative to 
non-cannabis users on the Barratt Impulsiveness Scale (BIS-11). In fact, impulsivity is 
well documented among individuals who use substances and has been shown to be a risk 
factor and predictor of substance use disorders (Guy, Smith, & Bentler, 1994; Poulton & 
Hester, 2019). Among recreational cannabis users, one study found that individuals with 
higher levels of impulsivity held fewer negative expectancies related to cannabis use and, 
consequently, used cannabis more frequently than those with lower levels of impulsivity 
(Vangsness, Bry, & LaBouvie, 2005). In addition, inhibitory functioning assessed via 
objective, cognitive paradigms also plays an important role in predicting risk for 
substance use disorders. For example, one study reported that poorer performance on 
inhibitory tasks prior to the initiation of cannabis use predicted increased cannabis use by 
late adolescence (Squeglia et al., 2014). Taken together, this evidence suggests that 
impulsivity/inhibition may be an important moderator in the development CUD. 
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To date, no published studies have assessed impulsivity in MC patients. Although 
not reported in Chapters 3 and 4, MC patients included in the current analyses also 
completed the Barratt Impulsiveness Scale (BIS-11) as part of the ongoing longitudinal 
study. At baseline, prior to initiation of substance use, MC patients reported impulsivity 
levels (BIS-11 average total score: 58.39) which are quite similar to levels reported by 
healthy controls included in Chapter 2 (BIS-11 average total score: 56.12), and notably 
lower than that of the recreational cannabis users in Chapter 2 (BIS-11 average total 
score: 65.03). It is possible that lower baseline impulsivity could serve as a protective 
factor against development of CUD symptoms. For example, lower levels of impulsivity 
may allow MC patients to use cannabis to the point of symptom alleviation and then stop, 
rather than continuing to use more cannabis for the rewarding effects of euphoria or 
feeling high. Once appropriate and valid tools are developed for screening assessments of 
CUD, specifically in MC patients, research exploring the relationship between 
impulsivity and CUD symptoms in MC patients will be beneficial, as it is possible that 
baseline levels of impulsivity may moderate, and therefore predict, risk for CUD in MC 
patients as well. 
In addition, recreational users by definition use cannabis to change their current 
state or get high, which is accomplished by using products high in THC. Accordingly, 
recreational cannabis users may be at increased risk for CUD due to the fact that cannabis 
with higher THC content produces stronger reinforcing effects (Curran et al., 2016; 
Justinova, Goldberg, Heishman, & Tanda, 2005). Importantly, theories of addiction posit 
that intoxication produces pleasurable feelings and therefore reinforcing effects, which 
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ultimately leads to repeated use in order to continue to achieve the rewarding effects 
produced by the drug. Ultimately, reinforcement is implicated in drug use transitioning 
from voluntary to compulsive (Everitt & Robbins, 2016). Further, use of cannabis with 
higher THC content has been shown to be associated with greater addiction severity 
(Freeman & Winstock, 2015b). In contrast, one study found that individuals who 
consumed cannabis with higher amounts of CBD were less likely to show an attentional 
bias to cannabis-related images (Morgan, Freeman, Schafer, & Curran, 2010). These 
findings support the idea that CBD may protect against the development of CUD, as 
attentional bias to drug-related stimuli is correlated with symptoms of substance use 
disorders. Given that MC patients in the current studies were shown to have higher CBD 
exposure relative to THC, product choice may also be related to a lower risk for the 
development of problematic cannabis use among MC patients. 
In light of these key differences between recreational users and MC patients, 
empirical studies directly comparing these two groups are warranted. However, it is 
difficult to statistically compare the current cohorts given the number of critical 
differences between the two groups, including age, duration of cannabis use, and 
presence of medical or psychiatric disorders. In addition, given that exposure to specific 
cannabinoids appears to mediate cognitive outcomes, it will be important for this type of 
data to be incorporated into any comparison of recreational users versus MC patients; 
unfortunately, cannabinoid exposure data based on laboratory analyses of products used 
is not available for the majority of recreational cannabis users in the current dataset, and 
is not included in most published studies to date. Prospective studies recruiting well-
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matched recreational and medical cannabis-using cohorts are needed to further assess 
differential effects of cannabis on cognition in these unique populations.  
Potential Public Health Considerations 
 Findings from this set of studies raise a number of important questions and 
although results are considered preliminary, results of these detailed in-person studies 
also raise potential considerations regarding cannabis-related public health and public 
policy. Although cognitive decrements were not observed in the recreational cohort, 
given results of previous studies, it would appear safest to avoid recreational cannabis use 
during the vulnerable window of neuromaturation. Additional data, however, are needed 
guide policymakers in proposing age restrictions. Public health efforts should focus on 
delaying cannabis use, given that the risk of cognitive insult is likely to be lower in adults 
who are neurodevelopmentally mature.  
 In forming public policy, lawmakers and health officials are encouraged to 
remember that not all cannabis confers the same risks or benefits; the impact of 
individual cannabinoids must be considered. For example, preliminary data from 
hypothesis-generating analyses raise the possibility that higher urinary THC levels may 
be related to poorer cognitive performance. Additionally, pilot data (see Chapter 2 
Discussion) from a subsample of recreational users recruited for the most recent study 
provides additional evidence that recreational users may be using more potent products 
than in years prior, which could negatively affect cognition. Studies with larger sample 
sizes and additional data are needed given that the potential for negative effects related to 
potency could be additive with the negative effects typically associated with adolescent 
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onset of cannabis use. Nevertheless, it may be helpful to consider imposing limits on 
THC content in recreational products to mitigate potential risk and harm. Similarly, given 
potentially protective factors of CBD, it may also be helpful to set thresholds for 
minimum levels of constituents with potentially beneficial effects. For example, results 
from Chapter 4 suggest that higher CBD exposure may related to improvements in mood, 
anxiety, and quality of life.  Results, however, are preliminary, and additional research 
will be critical in helping to guide decisions about limiting or setting minimums for 
individual cannabinoid content. 
 Cannabis use is currently widespread throughout the nation both recreationally 
and medically. As such, it is important to monitor whether changes in legalization 
ultimately influence rates of CUD. In addition, it will be important for researchers to 
assess whether specific patterns of use confer differential levels of risk for the 
development of problematic use or CUD (e.g., medical versus recreational goal of use; 
use of high potency products versus use of low-THC products that also contain other non-
intoxicating and potentially beneficially cannabinoids). While a number of measures exist 
to assess CUD in recreational users, to accomplish this goal, it will be critical to develop 
valid tools specifically to assess CUD in those who use cannabis medically. 
 Finally, findings from the current studies also help to highlight important gaps in 
the literature which will need to be addressed in order to more thoroughly understand 
both the positive and the negative effects related to cannabis use. For example, it will be 
helpful to gather data on younger cohorts of MC patients, older cohorts of recreational 
users, and individuals who use cannabis both medically and recreationally. Despite these 
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research gaps, some institutions have begun to draft guidelines for cannabis consumers 
who are interested in minimizing risks. In general, recommendations include delaying use 
until after adolescence, choosing products with lower levels of THC, and limiting 
cannabis use overall (Fischer et al., 2017).  
 Clearly, although cannabis has been studied for decades, there is still much more 
to learn. Early research efforts treated cannabis as if it were a single, homogenous plant 
used for one reason – to get high. However, researchers and consumers alike have more 
recently begun to conceptualize cannabis as a heterogenous, complex plant that can be 
used in a variety of ways for a variety of reasons. This newer, yet more accurate view of 
cannabis has raised a number of important questions which make it difficult to draw 
straightforward, overarching conclusions about the impact of “cannabis,” as the term 
cannabis refers to a multitude of different plants, products, and formulations. In order to 
answer the many questions about the impact of cannabis use, it is necessary to explore the 
various individual constituents of the cannabis plant as well as the unique factors which 





Figure A.1. Standard Metric of THC and CBD Use: Example Calculation
Standard Metric of THC & CBD Use: Example Calculation 
 
Tincture 
CW extra strength, 100mL bottle, 1.2mL per dropper 
Patient uses 2 droppers per day  
Values from lab analysis (0.56mg/mL THC per mL and 17.43mg/mL CBD) 
 
• mL per week: 1.2mL x 2 droppers x 7 days = 16.8mL per week 
• THC per week: 16.8mL per wk x   0.56mg THC per mL =     9.41mg THC/week 
• CBD per week: 16.8mL per wk x 17.43mg CBD per mL = 292.82mg CBD/week 
 
Flower  
Strain: Bubba Kush Hemp 
Patient used 0.5g in 5 weeks 
Values from lab analysis (0.71% Total THC and 18.52% Total CBD) 
 
• g per week: 0.5g/5 weeks = 0.1g OR 100mg per week 
• mg THC per week: 100mg x 0.0071 CBD = 0.71mg THC/week 
• mg CBD per week: 100mg x 0.1852 THC = 18.52mg CBD/week 
 
Concentrate – vape cartridge  
500mg cartridge of Granddaddy Purple 
One cartridge lasts 3 weeks 
Values from product label (78.47% Total THC and 0.18% Total CBD) 
 
• mg per week: 500mg/3 weeks = 166.67mg  
• mg THC per week: 166.67 x 0.7847 THC = 130.79mg THC 
• mg CBD per week: 166.67 x 0.0018 CBD = 0.30mg CBD 
 
Edible 
Jar of honey containing 23 servings of hemp 
Product label: 0 mg THC, 5mg CBD per serving 
Patient used 1 serving each morning with breakfast 
 
• mg THC per week: 0mg THC x 7 servings  =  0.00mg THC per week 
• mg CBD per week: 5mg CBD x 7 servings = 35.00mg CBD per week  
 
 
Overall product totals  
THC =     9.41mg +   0.71mg + 130.79mg +  0.00mg  =  
CBD = 292.82mg + 18.52mg +    0.30mg + 35.00mg =  
 
140.91mg TOTAL THC per week 
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